Wiskott-Aldrich syndrome: Difference between revisions

	WikiDoc Resources for Wiskott-Aldrich syndrome
Articles
Most recent articles on Wiskott-Aldrich syndrome Most cited articles on Wiskott-Aldrich syndrome Review articles on Wiskott-Aldrich syndrome Articles on Wiskott-Aldrich syndrome in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Wiskott-Aldrich syndrome Images of Wiskott-Aldrich syndrome Photos of Wiskott-Aldrich syndrome Podcasts & MP3s on Wiskott-Aldrich syndrome Videos on Wiskott-Aldrich syndrome
Evidence Based Medicine
Cochrane Collaboration on Wiskott-Aldrich syndrome Bandolier on Wiskott-Aldrich syndrome TRIP on Wiskott-Aldrich syndrome
Clinical Trials
Ongoing Trials on Wiskott-Aldrich syndrome at Clinical Trials.gov Trial results on Wiskott-Aldrich syndrome Clinical Trials on Wiskott-Aldrich syndrome at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Wiskott-Aldrich syndrome NICE Guidance on Wiskott-Aldrich syndrome NHS PRODIGY Guidance FDA on Wiskott-Aldrich syndrome CDC on Wiskott-Aldrich syndrome
Books
Books on Wiskott-Aldrich syndrome
News
Wiskott-Aldrich syndrome in the news Be alerted to news on Wiskott-Aldrich syndrome News trends on Wiskott-Aldrich syndrome
Commentary
Blogs on Wiskott-Aldrich syndrome
Definitions
Definitions of Wiskott-Aldrich syndrome
Patient Resources / Community
Patient resources on Wiskott-Aldrich syndrome Discussion groups on Wiskott-Aldrich syndrome Patient Handouts on Wiskott-Aldrich syndrome Directions to Hospitals Treating Wiskott-Aldrich syndrome Risk calculators and risk factors for Wiskott-Aldrich syndrome
Healthcare Provider Resources
Symptoms of Wiskott-Aldrich syndrome Causes & Risk Factors for Wiskott-Aldrich syndrome Diagnostic studies for Wiskott-Aldrich syndrome Treatment of Wiskott-Aldrich syndrome
Continuing Medical Education (CME)
CME Programs on Wiskott-Aldrich syndrome
International
Wiskott-Aldrich syndrome en Espanol Wiskott-Aldrich syndrome en Francais
Business
Wiskott-Aldrich syndrome in the Marketplace Patents on Wiskott-Aldrich syndrome
Experimental / Informatics
List of terms related to Wiskott-Aldrich syndrome

VisualWikitext

Latest revision as of 16:55, 14 December 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [2]; Syed Hassan A. Kazmi BSc, MD [3]; Cafer Zorkun, M.D., Ph.D. [4]

Synonyms and keywords: Aldrich syndrome

Overview

Wiskott-Aldrich syndrome (WAS) is a rare X-linked recessive disease characterized by eczema, thrombocytopenia (low platelet counts), immune deficiency, and bloody diarrhea (due to the low platelet counts). It is also sometimes called the eczema-thrombocytopenia-immunodeficiency syndrome in keeping with Aldrich's original description in 1954.^[1] The WAS-related disorders of X-linked thrombocytopenia (XLT) and X-linked congenital neutropenia (XLN) may present similar but less severe symptoms and are caused by mutations of the same gene.

Historical Perspective

The syndrome is named after Dr Robert Anderson Aldrich, an American pediatrician who described the disease in a family of Dutch-Americans in 1954, and Dr Alfred Wiskott, a German pediatrician who first noticed the syndrome in 1937.^[2] Wiskott described three brothers with a similar disease, whose sisters were unaffected. In 2006 a German research group analysed family members of Wiskott's three cases, and surmised that they probably shared a novel frameshift mutation of the first exon of the WAS gene.^[3]

Classification

Jin et al (2004) employ a numerical grading of severity:^[4]

Grade 0.5: intermittent thrombopenia
Grade 1.0: thrombopenia and small platelets
Grade 2.0: thrombopenia and normally responsive eczema or occasional upper respiratory tract infections.
Grade 2.5: thrombopenia and therapy-responsive but severe eczema or airway infections requiring antibiotics
Grade 3.0: both eczema and airway infections requiring antibiotics
Grade 4.0: eczema continuously requiring therapy and/or severe or life threatening infections
Grade 5.0: autoimmune disease or malignancy in an XLT/WAS patient.

Pathophysiology

In the Wiskott–Aldrich syndrome, the platelets are small and do not function properly. They are removed by the spleen, which leads to low platelet counts.

Wiskott–Aldrich syndrome was linked in 1994 to mutations in a gene on the short arm of the X chromosome, which was termed Wiskott-Aldrich syndrome protein (WASp). It was later discovered that the disease X-linked thrombocytopenia (XLT) was also due to WASp mutations, but different ones from those that cause full-blown Wiskott–Aldrich syndrome. Furthermore, the rare disorder X-linked neutropenia has been linked to particular mutations of the WASp gene.

The WASp gene codes for the protein by the same name, which is 502 amino acids long and is mainly expressed in hematopoietic cells (the cells in the bone marrow that develop into blood cells). The main function of WASp is to activate actin polymerization by binding to the Arp2/3 complex. In T-cell, WASp is important because it is known to be activated via T-cell receptor (TCR) signaling pathways to induce cortical actin cytoskeleton rearrangements that are responsible for forming the immunological synapse.

The immune deficiency is caused by decreased antibody production, and an inability for T cells to become polarized ^[5] (making it a combined immunodeficiency). This leads to increased susceptibility to infections, particularly of the ears and sinuses. T cells are unable to reorganize their actin cytoskeleton. The type of mutation to the WASp gene correlates significantly with the degree of severity: those that led to the production of a truncated protein caused significantly more symptoms than those with a missense mutation but a normal-length WASp. Although autoimmune disease and malignancy occur in both types of mutation, those patients with truncated WASp carry a higher risk.

A defect in CD43 molecule has been found to be associated in patients with Wiskott–Aldrich syndrome.^[6]

Causes

In Wiskott–Aldrich syndrome, the platelets are small and do not function properly. They are removed by the spleen, which leads to low platelet counts.

Wiskott–Aldrich syndrome was linked in 1994 to mutations in a gene on the short arm of the X chromosome, which was termed Wiskott-Aldrich syndrome protein (WASp). It was later discovered that the disease X-linked thrombocytopenia (XLT) was also due to WASp mutations, but different ones from those that cause full-blown Wiskott–Aldrich syndrome. Furthermore, the rare disorder X-linked neutropenia has been linked to particular mutations of the WASp gene.

The WASp gene codes for the protein by the same name, which is 502 amino acids long and is mainly expressed in hematopoietic cells (the cells in the bone marrow that develop into blood cells). The main function of WASp is to activate actin polymerization by binding to the Arp2/3 complex. In T-cell, WASp is important because it is known to be activated via T-cell receptor (TCR) signaling pathways to induce cortical actin cytoskeleton rearrangements that are responsible for forming the immunological synapse.

The immune deficiency is caused by decreased antibody production, and an inability for T cells to become polarized ^[5] (making it a combined immunodeficiency). This leads to increased susceptibility to infections, particularly of the ears and sinuses. T-cells are unable to reorganize their actin cytoskeleton. The type of mutation to the WASp gene correlates significantly with the degree of severity: those that led to the production of a truncated protein caused significantly more symptoms than those with a missense mutation but a normal-length WASp. Although autoimmune disease and malignancy occur in both types of mutation, those patients with truncated WASp carry a higher risk.

A defect in CD43 molecule has been found to be associated in patients with Wiskott–Aldrich syndrome.^[6]

Differentiating Wiskott-Aldrich Syndrome From Other Disorders of Humoral Imuunodeficiency

Wiskott-Aldrich Syndrome should be differentiated from other disorders leading to hypogammaglobulinemia and defects of humoral immunity. The following conditions may be considered as differentials:^[7]^[8]^[9]^[10]^[11]^[12]^[13]^[14]^[15]^[16]^[17]^[18]^[19]^[20]^[21]^[22]^[23]^[24]^[25]^[26]^[27]^[28]^[29]^[30]^[31]^[32]^[33]^[34]^[30]^[35]^[36]^[37]^[38]^[39]^[40]^[41]^[42]^[43]^[44]^[45]^[46]^[47]^[48]^[49]^[50]^[51]^[52]^[53]^[54]^[55]^[56]

Disorder	Mechanism	Characteristic Features	Clinical Presentation	Laboratory Findings
Wiskott-Aldrich Syndrome	Mutation in WAS gene T cells unable to reorganize actin microfilaments (microfilament defect)	X-linked recessive pattern of inheritance Increased risk of autoimmune disease and malignancy	Thrombocytopenic purpura Eczema Recurrent infections	Decreased to normal IgG and IgM Increased IgE and IgA Fewer and smaller platelets
X-Linked (Bruton) Agammaglobulinemia	Defect in tyrosine kinase gene (BTK) B cells fail to mature	X-linked recessive pattern of inheritance Increased prevalence in males	Recurrent bacterial and enteroviral infections after 6 months of age Pre-disposition to development of infections by encapsulated organisms Pre-disposition to development of Giardia infections Absent lymph nodes and tonsils	Normal CD19+ B cell count Decreased pro-B cells Increased pre-B cells Decreased immunoglobulins of all classes
Selective IgA Deficiency	Stem cell defect (Transferrable with marrow transplant) Lack of IL-4, IL-6, IL-7, IL-10, TGF-β, and IL-21 Mutations in transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI, TNFRSF13B)	Most common primary immune deficiency	Majority of the cases are asymptomatic Respiratory and gastrointestinal infections (mucosal infections) Associated with autoimmune diseases Atopy Anaphylaxis to IgA containing products	Serum IgA < 7 mg/dl Normal IgG and IgM levels
Common Variable Immunodeficiency	Defective B cell differentiation	May be acquired in 20-30 years of age	May present with other autoimmune diseases Associated with bronchiectasis Associated with lymphoma Associated with sinopulmonary infections (Bacterial, enteroviral and parasitic such as Giardia)	Decreased plasma cells Decreased immunoglobulins
Autosomal dominant hype IgE syndrome (Job's Syndrome)	Defieciency of Th17 cells due to STAT3 mutation Impaired neutrophils to sites of infection	Distinctive coarse facies Cold (non-inflammatory) Staphylococcal abscesses Retained primary teeth Eczema		Increased levels of IgE Decreased levels of interferon gamma (IFN-gamma)
Severe combined immunodeficiency (SCID)	Defective interleukin-2 receptor gamma chain Adenosine deaminase deficiency Reg 1 and Reg 2 nonsense mutations	IL-2R disease is X-linked ADA deficiency and reg mutations are typically autosomal recessive	Failure to thrive Chronic diarrhea Thrush Recurrent bacterial, viral and protozoal infections Treatment is bone marrow transplant	Decreased T cell receptor excision circles (TRECs) Abscence of thymic shadow on chest X-Ray Absent germinal centers of lymph node biopsy Absent T cells on flow cytometry
Ataxia Telangiectasia	Defect in ATM gene DNA double stranded breaks leading to cell cycle arrest	Hypersensitivity to X-Rays	Triad of: Ataxia Spider angiomas (Nests of distended capillaries) IgA deficiency	Increased alpha fetoprotein (AFP) Decreased IgA, IgG and IgE Lymphopenia Cerebellar atrophy
Hyper IgM Syndrome	Defective CD40L (CD40 ligand) on Th cells leading to class switching defect	X-linked recessive pattern of inheritance	Severe pyogenic infections in early life Opportunistic infection with: Pneumocystis jiroveci Cryptosporidium Cytomegalovirus (CMV)	Increased IgM Decreased IgG, IgA and IgE No germinal centers

Malignancy: can cause the reduction in the immunoglobulin production.

Viral infections: such as Epstein-Barr virus, HIV, cytomegalovirus are other causes of hypogammaglobulinemia..
Side effect of certain medications: Some drugs include systemic glucocorticoids, phenytoin, and carbamazepine, have been associated with IgG deficiency.
Other causes of primary humoral immunodeficiencies.
Smoking: may cause IgG2 subclass deficiency.
Protein-losing conditions: enteropathies, nephrotic syndrome, burns, and other traumas may cause abnormal loss of immunoglobulins.

Differentiating Wiskott-Aldrich Syndrome From Other Bleeding Diseases

Wiskott-Aldrich syndrome must be differentiated from other bleeding disorders. Different causes of bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings. These features have discussed in the below table:

Category	Subcategory	Disease		History	Clinical manifestation						Laboratory testing					Comments
Category	Subcategory	Disease		History	Mucosal bleeding	Petechia	Ecchymoses	Menorrhagia	Hematoma	Hemarthrosis	Plt	BT	PT	PTT	TT	Comments
Platelet disorders	Qualitative Disorders of Platelet Function	Inherited Disorders of Platelet Function	Wiskott-Aldrich syndrome	Positive family history	+	+	+	+	−	−	Nl or ↓	↑	Nl	Nl	Nl	Anti-WASP antibody can be used to detect presence or absence of WAS protein In Wiskott–Aldrich syndrome, the platelets are small and do not function properly. They are removed by the spleen, which leads to low platelet counts.
			Glanzmann’s thrombasthenia	Positive family history	+	+	+	+	−	Rare	Nl or ↓	↑	Nl	Nl	Nl	AR inheritance Absence of the platelet Gp IIb/IIIa receptor Diminished for GP 2B-3A on flow cytometry
			Bernard-Soulier syndrome	Positive family history	+	+	+	+	−	−	Nl or ↓	↑	Nl	Nl	Nl	AR inheritance Absence of the platelet Gp Ib-IX-V receptor On PBS: giant platelets Ristocetin - no aggregation
			Platelet storage pool disorder: Hermansky-Pudlak syndrome Chediak-Higashi syndrome Gray platelet syndrome	Positive family history Hairy cell leukemia Cardiovascular bypass	+	+	+	+	−	−	Nl or ↓	↑	Nl	Nl	Nl	AD inheritance AbNlities of platelet granule formation
		Acquired Disorders of Platelet Function		Uremia Cardiopulmonary bypass Hematologic disorders such as: myeloproliferative and myelodysplastic syndromes	+	+	+	+	±	±	Nl or ↓	↑	Nl	Nl	Nl	−
		Von Willebrand Disease		Easy bruising Epistaxis Oral cavity bleeding Bleeding after dental extraction/surgery Menorrhagia Postpartum hemorrhage	+	+	+	+	±	±	↑	Nl	↑	↑	Nl	See the table below for the details about different types.
	Subcategory	Disease		History	Mucosal bleeding	Petechia	Ecchymoses	Menorrhagia	Hematoma	Hemarthrosis	Plt	BT	PT	PTT	TT	Comments
	Thrombocytopenia	Infection-Induced thrombocytopenia		History of prior infection	+	+	+	+	+	+	↓	↑	Nl	Nl	Nl	−
		Medication-Induced Thrombocytopenia		History of medications such as: Furosemide Nonsteroidal anti-inflammatory drugs (NSAIDs) Penicillin Quinidine Quinine Ranitidine Sulfonamides Linezolid	+	+	+	+	+	+	↓	↑	Nl	Nl	Nl	Most important part of treatment is discontinuing of the medication.
		Heparin-Induced thrombocytopenia		Thrombosis Unexplained thrombocytopenia up to 3 weeks after the end of heparin therapy	+	+	+	+	+	+	↓	↑	Nl	Nl	↑	For more information click here: Heparin-induced thrombocytopenia.
		Immune Thrombocytopenic Purpura		History of prior infection or no history	+	+	+	+	+	+	↓	↑	Nl	Nl	Nl	−
		Inherited Thrombocytopenia		Positive family history	+	+	+	+	+	+	↓	↑	Nl	Nl	Nl	−
		Thrombotic Thrombocytopenic Purpura		History of: Cancer Bone marrow transplantation Pregnancy Medication Platelet aggregation inhibitors (ticlopidine and clopidogrel) Immunosuppressants (cyclosporine, mitomycin, tacrolimus/FK506, interferon-α) HIV-1 infection	+	+	+	+	+	+	↓	↑	Nl	Nl	Nl	−
		Hemolytic Uremic Syndrome		History of: Infections Malignancy, chemotherapy, and ionizing radiation Calcineurin inhibitors and transplantation Pregnancy, HELLP syndrome, and oral contraceptive pill Systemic lupus erythematosis Antiphospholipid antibody syndrome Glomerulopathy	+	+	+	+	+	+	↓	↑	Nl	Nl	Nl	−
	Subcategory	Disease		History	Mucosal bleeding	Petechia	Ecchymoses	Menorrhagia	Hematoma	Hemarthrosis	Plt	BT	PT	PTT	TT	Comments
Vessel wall disorders	Metabolic and Inflammatory Disorders	Acute febrile illnesses Mixed cryoglobulinemia Monoclonal gammopathies Rocky Mountain spotted fever Vitamin C deficiency Cushing’s syndrome Chronic glucocorticoid therapy Vasculitis such as Henoch-Schönlein Purpura		History of the underlying disease	−	+	+	±	−	−	Nl	Nl or ↑	Nl	Nl	Nl	−
Vessel wall disorders	Inherited Disorders of the Vessel Wall	Marfan’s syndrome Ehlers-Danlos syndrome Pseudoxanthoma elasticum Hereditary hemorrhagic telangiectasia (HHT, or Osler-Weber-Rendu disease)		Positive family history	−	+	+	±	−	−	Nl	Nl or ↑	Nl	Nl	Nl	−
Coagulation factor disorders ^[57]	Fibrinogen deficiency	Different types of the fibrinogen disorders: Congenital afibrinogenemia Congenital hypofibrinogenemia Fibrinogen storage disease Congenital dysfibrinogenemia Hereditary fibrinogen Aα-Chain amyloidosis Acquired dysfibrinogenemia		Epistaxis Easy bruising Menorrhagia Muscle bleeds Hemarthrosis Bleeding from the umbilical cord stump after birth Bleeding after dental surgery or tooth extraction AbNl bleeding during or after injury, surgery, or childbirth Gastrointestinal hemorrhage Cerebral hemorrhage Thrombosis	−	−	+	+	±	+	Nl	↑	↑	↑	↑	Impaired fibrin cross-linking or clot dissolution Mild or severe bleeding idepend on levels of functional fibrinogen Variable age of onset
	Subcategory	Disease		History	Mucosal bleeding	Petechia	Ecchymoses	Menorrhagia	Hematoma	Hemarthrosis	Plt	BT	PT	PTT	TT	Comments
	Prothrombin deficiency			Epistaxis Soft-tissue hemorrhage Excessive postoperative bleeding Menorrhagia Muscle hematomas Hemarthrosis Intracranial bleeding	−	+	+	+	+	+	Nl	Nl	↑	↑	↑	−
	Factor V deficiency			Excessive bruising with minor injuries Epistaxis Hemarthrosis Menorrhagia Intracerebral hemorrhages Pulmonary hemorrhage	−	−	+	+	+	+	Nl	↑	↑	↑	Nl	The severity of bleeding related to the degree of factor V deficiency
	Factor VII deficiency			Easy bruising Mucosal bleeding Postoperative bleeding Menorrhagia Soft tissue hematomas Thrombosis				+	+	+	Nl		↑	Nl	Nl	Thrombosis in inherited factor VII deficiency Treatment with the administration of factor VII replacement therapy
	Factor X deficiency			Prolonged bleeding following circumcision Easy bruising Hematuria Menorrhagia Abortion Postpartum hemorrhage Epistaxis Pseudotumors Intracranial bleeding Hemarthroses		+	+	+	+	+	Nl	Nl	↑	↑	Nl	−
	Factor XII deficiency			Asymptomatic Recurrent miscarriages Painful leg ulcers		−	−	−	−	−	Nl	Nl	Nl	↑	Nl
	Subcategory	Disease		History	Mucosal bleeding	Petechia	Ecchymoses	Menorrhagia	Hematoma	Hemarthrosis	Plt	BT	PT	PTT	TT	Comments
	High molecular weight kininogen (HMWK) deficiency			Positive family history of bleeding		−	−	−	−	−	Nl	Nl	Nl	↑	Nl
	Prekallikrein deficiency			Positive family history of bleeding		−	−	−	−	−	Nl	Nl	Nl	↑	Nl
	Factor XIII deficiency	Sub unit A mutation disease (more common) Sub unit B mutation disease		Positive family history of bleeding	±	±	±	±	±	±	Nl	Nl	Nl or ↑	Nl	Nl	Impaired fibrin cross-linking or clot dissolution The severity of factor XIII deficiency bleeds can be different in different patients
	Hemophilia	Type A deficiency		Eeasy bruising Inadequate clotting in trauma or mild injury Spontaneous hemorrhage Hemarthrosis Epistaxis Gingival bleeding	−	−	−	+	+	+	Nl	Nl	Nl	↑	Nl	−
		Type B deficiency		Neonatal bleeding Trauma-related soft tissue hemorrhage Hemarthrosis Hematomas	−	−	−	+	+	+	Nl	Nl	Nl	↑	Nl	−
		Type C deficiency		Positive family history Bleeding after surgery or injury	−	−	−	+	Rare	Rare	Nl	Nl	Nl	↑	Nl	−
	Subcategory	Disease		History	Mucosal bleeding	Petechia	Ecchymoses	Menorrhagia	Hematoma	Hemarthrosis	Plt	BT	PT	PTT	TT	Comments
Rare diseases	Disseminated Intravascular Coagulation			Trauma Burn Crush injury Sepsis Malignancy Obstetric complication: abruption, amniotic fluid embolism Hemolytic anemia	+	+	+	+	+	+	↓	↑	↑	↑	Nl	−
Rare diseases	Vitamin K Deficiency			Bleeding after trauma Epistaxis Hematoma Gastrointestinal bleeding Menorrhagia Hematuria Gum bleeding Oozing from venipuncture sites Easy bruisability	+	−	+	+	+	+	Nl	↑	↑	Nl or mildly prolonged	Nl	−

Risk Factors

Positive family history of Wiskott-Aldrich syndrome, can be considered as a risk factor.

Screening

Flow cytometry:
- Anti-WASp antibody can be used to detect presence or absence of WAS protein. However, flow cytometry may not detect expression of mutated, reduced or poor WASp.^[58]
Identification of carriers: Known female carriers can be identified by using DNA mutation analysis of WAS gene.
Prenatal diagnosis: DNA analysis from chorionic villus sampling can be performed.^[59]

Natural History, Complications, and Prognosis

If left untreated, patients with Wiscott-Aldrich syndrome may progress to develop manifestations associated with thrombocytopenia, and abnormal platelet function, defective innate and adaptive immunity which include, severe bleeding (eg, epistaxis, purpura, life threatening gastrointestinal and intracranial hemorrhages), recurrent and severe bronchopulmonary infections. Malignancy and autoimmunity risk has also increased. These conditions may increase the risk of death.^[60]
Common complications of Wiscott-Aldrich syndrome include:
- Recurrent infections with bacterial, viral, fungal and opportunistic organisms. Most common clinical manifestations include otitis media, sinusitis, pneumonia, meningitis, skin infections, and sepsis.^[61]^[62]^[63]
- Bleeding diathesis (eg, epistaxis, ecchymoses, petechiae, hematemesis, intracranial and gastrointestinal hemorrhages)^[60]^[64]
- Autoimmune manifestations may occur in the form of autoimmune hemolytic anemia, immune thrombocytopenic purpura and neutropenia, vasculitis involving small and large vessels, inflammatory bowel disease, and immune-mediated damage to the kidneys and joints.^[65]^[66]^[67]
- Increased risk of malignancy such as lymphoma, leukaemia is a frequent occurence in Wiskott-Aldrich syndrome.^[68]^[69]
Prognosis is generally poor. 5-year survival rates in patients with Wiscott-Aldrich syndrome who had received stem cell transplantation is approximately 73.7% to 80%.^[70]

Diagnosis

Diagnostic Study of Choice

The first laboratory test to be performed in the diagnosis of Wiskott-Aldrich syndrome is complete blood count with differential and peripheral blood smears.
The diagnosis of Wiskott-Aldrich syndrome is suspected if a male patient who presents with bruises, petechiae, eczema, recurrent infections and the presence of congenital thrombocytopenia(< 70 000/mm3) with small platelet volume <5·0fl (micro thrombocytopenia) on the peripheral blood smear.
Identification of WAS gene mutations using DNA sequence analysis of WAS gene and detection of WASp expression by flow cytometry are necessary to confirm the diagnosis.^[71]^[63]

History and Symptoms

Patients with Wiskott-Aldrich syndrome have

Common symptoms of Wiskott-Aldrich syndrome include:
- Easy bruising
- Petechiae
- Purpura
- Eczema
- Prolonged and excessive bleeding after circumcision or from umbilical stump
- Recurrent infections
- Epistaxis (Nose bleeds)
- Hematemesis
- Hematuria
- Melena

Physical Examination

The following findings may be found in the physical examination of the patients with Wiscott-Aldrich syndrome. These include:^[72]^[73]
- Failure to thrive
- Skin examination shows bruises, petechiae, purpura, and eczema due to low platelet count. suppurative skin lesions may also be seen.
- Lymphadenopathy
- Rales and wheezing on auscultation if there is an underlying lung infection.
- Hepatosplenomegaly
- ENT examination: Carefully examine sinuses to rule out sinusitis, ears for any tympanic membrane abnormalities to rule out otitis media and throat for pharyngitis and other opportunistic infections such as oral thrush.
- CNS examination may be performed for symptoms associated with intracranial hemorrhage and infections.

Laboratory Findings

Laboratory findings consistent with the diagnosis of Wiscott-Aldrich syndrome include:
- Complete blood count (CBC) and peripheral smear may show anemia, thrombocytopenia, decreased platelet size and volume.^[74]
- Immunologic studies may show following findings:^[75]^[76]^[77]
  - Decreased levels of serum IgG and IgM and elevated levels of serum IgA and IgE antibodies.
  - Reduction in T lymphocyte count and their function.
  - Variable antibody response to vaccines, protein and polysaccharide antigens.
  - Decreased or absent concentrations of isohemagglutinins.
  - Abnormal T and B lymphocyte proliferative response to mitogens.
  - Abnormal phagocytic response
  - Natural Killer cell defects may also be found.

Electrocardiogram

There are no specific electrocardiogram findings associated with Wiskott-Aldrich syndrome.

X-ray

There are no specific x-ray findings associated with Wiskott-Aldrich syndrome. However, a chest x-ray may be helpful in the diagnosis of complications, which include pneumonia.

Echocardiography or Ultrasound

There are no specific echocardiography/ ultrasound findings associated with Wiscott-Aldrich syndrome.

CT scan

There are no CT scan findings associated with Wiscott-Aldrich syndrome. However, a CT scan may be helpful in the diagnosis of complications of this syndrome, which include pneumonia, internal hemorrhage, to diagnose malignancy and to assess splenic enlargement.^[78]

MRI

There are no specific MRI findings associated with Wiskott-Aldrich syndrome.

Treatment

Medical Therapy

Mainstay therapy for Wiskott-Aldrich syndrome is conservative therapy and supportive care, which includes:
- Prophylactic antimicrobial agents should be given to treat bacterial, viral, fungal and opportunistic infections.^[79]^[80]
  - Trimethoprim/sulfamethoxazole: 5mg/kg/day can be given to treat most bacterial and pneumocystis jirovecii pneumonia.
  - Acyclovir: 200mg/twice daily may be given to treat viral infections (eg, HSV-1)^[81]
  - Fluconazole: 3mg/kg/day may be given to treat fungal infections.
- Platelet transfusions:^[82]
  - Platelet transfusions can be given to treat bleeding episodes such as life-threatening gastrointestinal and intracranial hemorrhages. Platelet transfusions can also be given to patients who are undergoing any surgical procedure.
  - If a patient can be chosen for transfusion, platelets and blood products should be irradiated and must be obtained from a CMV free donor.
- Intravenous immunoglobulins:^[83]
  - Preferred regimen: 400 to 600 mg/kg can be given every three weeks
- Immunosuppressive agents:^[84] Rituximab can be given to treat autoimmune cytopenias such as hemolytic anemia, neutropenia, associated with Wiskott- Aldrich syndrome.
- Thrombopoietic agents: Eltrombopag may be helpful in increasing platelet count in patients with Wiskott-Aldrich syndrome but it may not improve platelet surface activation.^[85]
- Gene therapy: Gene therapy is an alternative curative treatment for Wiskott-Aldrich syndrome, which is still going under trials.^[86]

Surgery

Hematopoietic stem cell transplantation (HSCT):^[87]^[88]^[89]
- HSCT is the only standard curative treatment for Wiskott-Aldrich syndrome.
Splenectomy: Splenectomy may be considered for some patients with Wiskott-Aldrich syndrome . Splenectomy may be found to improve platelet count as well as size of the platelets . However, sepsis is a life-threatening complication after splenectomy. Prophylactic antibiotics should always be used to prevent infections.^[90]^[91]

Primary Prevention

There are no established measures for the primary prevention of the Wiskott-Aldrich syndrome. However genetic mutation analysis and prenatal molecular diagnosis can be helpful in decreaing the occurance .^[92]^[59]

Secondary Prevention

There are no established measures for the secondary prevention of the Wiskott-Aldrich syndrome.

References

↑ Aldrich RA, Steinberg AG, Campbell DC (1954). "Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea". Pediatrics. 13 (2): 133–9. PMID 13133561.
↑ Wiskott, A (1937). "Familiärer, angeborener Morbus Werlhofii? ("Familial congenital Werlhof's disease?")". Montsschr Kinderheilkd. 68: 212–16.
↑ Binder V, Albert MH, Kabus M, Bertone M, Meindl A, Belohradsky BH (2006). "The genotype of the original Wiskott phenotype". N. Engl. J. Med. 355 (17): 1790–3. doi:10.1056/NEJMoa062520. PMID 17065640.
↑ Jin Y, Mazza C, Christie JR; et al. (2004). "Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation". Blood. 104 (13): 4010–9. doi:10.1182/blood-2003-05-1592. PMID 15284122.
↑ ^5.0 ^5.1 "Wiskott-Aldrich Syndrome: Immunodeficiency Disorders: Merck Manual Professional". Retrieved 2008-03-01.
↑ ^6.0 ^6.1 PMID 1683685 (PMID 1683685)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
↑ Agarwal S, Cunningham-Rundles C (September 2007). "Assessment and clinical interpretation of reduced IgG values". Ann. Allergy Asthma Immunol. 99 (3): 281–3. doi:10.1016/S1081-1206(10)60665-5. PMC 3099256. PMID 17910333.
↑ Korthäuer U, Graf D, Mages HW, Brière F, Padayachee M, Malcolm S, Ugazio AG, Notarangelo LD, Levinsky RJ, Kroczek RA (February 1993). "Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM". Nature. 361 (6412): 539–41. doi:10.1038/361539a0. PMID 7679206.
↑ Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, Resnick I, Fasth A, Baer M, Gomez L, Sanders EA, Tabone MD, Plantaz D, Etzioni A, Monafo V, Abinun M, Hammarstrom L, Abrahamsen T, Jones A, Finn A, Klemola T, DeVries E, Sanal O, Peitsch MC, Notarangelo LD (July 1997). "Clinical spectrum of X-linked hyper-IgM syndrome". J. Pediatr. 131 (1 Pt 1): 47–54. PMID 9255191.
↑ Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, Stiehm ER, Conley ME (November 2003). "The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients". Medicine (Baltimore). 82 (6): 373–84. doi:10.1097/01.md.0000100046.06009.b0. PMID 14663287.
↑ Subauste CS, Wessendarp M, Sorensen RU, Leiva LE (June 1999). "CD40-CD40 ligand interaction is central to cell-mediated immunity against Toxoplasma gondii: patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimer". J. Immunol. 162 (11): 6690–700. PMID 10352287.
↑ Hayward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A, Bonnefoy JY, Cosyns M, Weinberg A (January 1997). "Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM". J. Immunol. 158 (2): 977–83. PMID 8993019.
↑ Davies EG, Thrasher AJ (April 2010). "Update on the hyper immunoglobulin M syndromes". Br. J. Haematol. 149 (2): 167–80. doi:10.1111/j.1365-2141.2010.08077.x. PMC 2855828. PMID 20180797.
↑ Yel L (January 2010). "Selective IgA deficiency". J. Clin. Immunol. 30 (1): 10–6. doi:10.1007/s10875-009-9357-x. PMC 2821513. PMID 20101521.
↑ Suzuki H, Kaneko H, Fukao T, Jin R, Kawamoto N, Asano T, Matsui E, Kasahara K, Kondo N (March 2009). "Various expression patterns of alpha1 and alpha2 genes in IgA deficiency". Allergol Int. 58 (1): 111–7. doi:10.2332/allergolint.O-08-549. PMID 19153537.
↑ Cunningham-Rundles C (September 2001). "Physiology of IgA and IgA deficiency". J. Clin. Immunol. 21 (5): 303–9. PMID 11720003.
↑ Edwards E, Razvi S, Cunningham-Rundles C (April 2004). "IgA deficiency: clinical correlates and responses to pneumococcal vaccine". Clin. Immunol. 111 (1): 93–7. doi:10.1016/j.clim.2003.12.005. PMID 15093556.
↑ Chipps BE, Talamo RC, Winkelstein JA (April 1978). "IgA deficiency, recurrent pneumonias, and bronchiectasis". Chest. 73 (4): 519–26. PMID 305332.
↑ Zinneman HH, Kaplan AP (September 1972). "The association of giardiasis with reduced intestinal secretory immunoglobulin A". Am J Dig Dis. 17 (9): 793–7. PMID 5056860.
↑ Aghamohammadi A, Cheraghi T, Gharagozlou M, Movahedi M, Rezaei N, Yeganeh M, Parvaneh N, Abolhassani H, Pourpak Z, Moin M (January 2009). "IgA deficiency: correlation between clinical and immunological phenotypes". J. Clin. Immunol. 29 (1): 130–6. doi:10.1007/s10875-008-9229-9. PMID 18683032.
↑ Janzi M, Kull I, Sjöberg R, Wan J, Melén E, Bayat N, Ostblom E, Pan-Hammarström Q, Nilsson P, Hammarström L (October 2009). "Selective IgA deficiency in early life: association to infections and allergic diseases during childhood". Clin. Immunol. 133 (1): 78–85. doi:10.1016/j.clim.2009.05.014. PMID 19541543.
↑ Jacob CM, Pastorino AC, Fahl K, Carneiro-Sampaio M, Monteiro RC (May 2008). "Autoimmunity in IgA deficiency: revisiting the role of IgA as a silent housekeeper". J. Clin. Immunol. 28 Suppl 1: S56–61. doi:10.1007/s10875-007-9163-2. PMID 18202833.
↑ Conley ME, Notarangelo LD, Etzioni A (December 1999). "Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies)". Clin. Immunol. 93 (3): 190–7. doi:10.1006/clim.1999.4799. PMID 10600329.
↑ Mayer RJ, Schiffer CA, Peterson BA, Silver RT, Cornwell GG, McIntyre OR, Rai KR, Budman DR, Ellison RR, Maguire M (June 1985). "Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I study". Semin. Oncol. 12 (2 Suppl 3): 84–90. PMID 4012343.
↑ Massaad MJ, Ramesh N, Geha RS (May 2013). "Wiskott-Aldrich syndrome: a comprehensive review". Ann. N. Y. Acad. Sci. 1285: 26–43. doi:10.1111/nyas.12049. PMID 23527602.
↑ Candotti F (January 2018). "Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome". J. Clin. Immunol. 38 (1): 13–27. doi:10.1007/s10875-017-0453-z. PMID 29086100.
↑ Sereni L, Castiello MC, Villa A (March 2018). "Platelets in Wiskott-Aldrich syndrome: Victims or executioners?". J. Leukoc. Biol. 103 (3): 577–590. doi:10.1189/jlb.5MR0617-257R. PMID 28851742.
↑ Blundell MP, Worth A, Bouma G, Thrasher AJ (2010). "The Wiskott-Aldrich syndrome: The actin cytoskeleton and immune cell function". Dis. Markers. 29 (3–4): 157–75. doi:10.3233/DMA-2010-0735. PMC 3835520. PMID 21178275.
↑ Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia Roncarolo M (June 2009). "Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome". Blood. 113 (25): 6288–95. doi:10.1182/blood-2008-12-115253. PMID 19351959.
↑ ^30.0 ^30.1 Fischer A (November 2000). "Severe combined immunodeficiencies (SCID)". Clin. Exp. Immunol. 122 (2): 143–9. PMC 1905779. PMID 11091267.
↑ Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, McBride OW, Leonard WJ (April 1993). "Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans". Cell. 73 (1): 147–57. PMID 8462096.
↑ Puck JM (November 1996). "IL2RGbase: a database of gamma c-chain defects causing human X-SCID". Immunol. Today. 17 (11): 507–11. PMID 8961626.
↑ Rowiński J, Souchier C, Czyba JC (1978). "DNA content of cells in human buccal smears. A preliminary study". Acta Histochem. 62 (2): 276–81. doi:10.1016/S0065-1281(78)80093-2. PMID 104530.
↑ Morgan G, Levinsky RJ, Hugh-Jones K, Fairbanks LD, Morris GS, Simmonds HA (December 1987). "Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency". Clin. Exp. Immunol. 70 (3): 491–9. PMC 1542189. PMID 3436096.
↑ Ballard RW, Cummings CW (August 1980). "Job's syndrome". Laryngoscope. 90 (8 Pt 1): 1367–70. PMID 7401839.
↑ Freeman AF, Holland SM (May 2008). "The hyper-IgE syndromes". Immunol Allergy Clin North Am. 28 (2): 277–91, viii. doi:10.1016/j.iac.2008.01.005. PMC 2683262. PMID 18424333.
↑ Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, Freeman AF, Demidowich A, Davis J, Turner ML, Anderson VL, Darnell DN, Welch PA, Kuhns DB, Frucht DM, Malech HL, Gallin JI, Kobayashi SD, Whitney AR, Voyich JM, Musser JM, Woellner C, Schäffer AA, Puck JM, Grimbacher B (October 2007). "STAT3 mutations in the hyper-IgE syndrome". N. Engl. J. Med. 357 (16): 1608–19. doi:10.1056/NEJMoa073687. PMID 17881745.
↑ Ling JC, Freeman AF, Gharib AM, Arai AE, Lederman RJ, Rosing DR, Holland SM (March 2007). "Coronary artery aneurysms in patients with hyper IgE recurrent infection syndrome". Clin. Immunol. 122 (3): 255–8. doi:10.1016/j.clim.2006.10.005. PMID 17098478.
↑ Hutto JO, Bryan CS, Greene FL, White CJ, Gallin JI (March 1988). "Cryptococcosis of the colon resembling Crohn's disease in a patient with the hyperimmunoglobulinemia E-recurrent infection (Job's) syndrome". Gastroenterology. 94 (3): 808–12. PMID 3338649.
↑ O'Connell AC, Puck JM, Grimbacher B, Facchetti F, Majorana A, Gallin JI, Malech HL, Holland SM (February 2000). "Delayed eruption of permanent teeth in hyperimmunoglobulinemia E recurrent infection syndrome". Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 89 (2): 177–85. doi:10.1067/moe.2000.103129. PMID 10673653.
↑ Tam JS, Routes JM (2013). "Common variable immunodeficiency". Am J Rhinol Allergy. 27 (4): 260–5. doi:10.2500/ajra.2013.27.3899. PMC 3901442. PMID 23883805.
↑ Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C (February 2012). "Morbidity and mortality in common variable immune deficiency over 4 decades". Blood. 119 (7): 1650–7. doi:10.1182/blood-2011-09-377945. PMC 3286343. PMID 22180439.
↑ Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, Viallard JF, Gardembas M, Galicier L, Schleinitz N, Suarez F, Soulas-Sprauel P, Hachulla E, Jaccard A, Gardeur A, Théodorou I, Rabian C, Debré P (May 2008). "Infections in 252 patients with common variable immunodeficiency". Clin. Infect. Dis. 46 (10): 1547–54. doi:10.1086/587669. PMID 18419489.
↑ Roifman CM, Rao CP, Lederman HM, Lavi S, Quinn P, Gelfand EW (April 1986). "Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia". Am. J. Med. 80 (4): 590–4. PMID 3963038.
↑ Yong PF, Thaventhiran JE, Grimbacher B (2011). ""A rose is a rose is a rose," but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011?". Adv. Immunol. 111: 47–107. doi:10.1016/B978-0-12-385991-4.00002-7. PMID 21970952.
↑ Salzer U, Chapel HM, Webster AD, Pan-Hammarström Q, Schmitt-Graeff A, Schlesier M, Peter HH, Rockstroh JK, Schneider P, Schäffer AA, Hammarström L, Grimbacher B (August 2005). "Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans". Nat. Genet. 37 (8): 820–8. doi:10.1038/ng1600. PMID 16007087.
↑ Quinti I, Soresina A, Spadaro G, Martino S, Donnanno S, Agostini C, Claudio P, Franco D, Maria Pesce A, Borghese F, Guerra A, Rondelli R, Plebani A (May 2007). "Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency". J. Clin. Immunol. 27 (3): 308–16. doi:10.1007/s10875-007-9075-1. PMID 17510807.
↑ Nissenkorn A, Ben-Zeev B (2015). "Ataxia telangiectasia". Handb Clin Neurol. 132: 199–214. doi:10.1016/B978-0-444-62702-5.00014-7. PMID 26564081.
↑ Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM (November 2016). "Ataxia telangiectasia: a review". Orphanet J Rare Dis. 11 (1): 159. doi:10.1186/s13023-016-0543-7. PMC 5123280. PMID 27884168.
↑ Crawford TO (December 1998). "Ataxia telangiectasia". Semin Pediatr Neurol. 5 (4): 287–94. PMID 9874856.
↑ Boder E (1985). "Ataxia-telangiectasia: an overview". Kroc Found Ser. 19: 1–63. PMID 2415689.
↑ Hoche F, Seidel K, Theis M, Vlaho S, Schubert R, Zielen S, Kieslich M (June 2012). "Neurodegeneration in ataxia telangiectasia: what is new? What is evident?". Neuropediatrics. 43 (3): 119–29. doi:10.1055/s-0032-1313915. PMID 22614068.
↑ BODER E, SEDGWICK RP (April 1958). "Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection". Pediatrics. 21 (4): 526–54. PMID 13542097.
↑ Sahama I, Sinclair K, Pannek K, Lavin M, Rose S (August 2014). "Radiological imaging in ataxia telangiectasia: a review". Cerebellum. 13 (4): 521–30. doi:10.1007/s12311-014-0557-4. PMID 24683014.
↑ Lin DD, Barker PB, Lederman HM, Crawford TO (January 2014). "Cerebral abnormalities in adults with ataxia-telangiectasia". AJNR Am J Neuroradiol. 35 (1): 119–23. doi:10.3174/ajnr.A3646. PMC 4106125. PMID 23886747.
↑ Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, Carson KA, Lederman HM (April 2004). "Immunodeficiency and infections in ataxia-telangiectasia". J. Pediatr. 144 (4): 505–11. doi:10.1016/j.jpeds.2003.12.046. PMID 15069401.
↑
↑ Chiang S, Vergamini SM, Husami A, Neumeier L, Quinn K, Ellerhorst T, Sheppard L, Gifford C, Buchbinder D, Joshi A, Ifversen M, Kleiner GI, Bussel JB, Chandrakasan S, Pesek RD, Pozos TC, Rose MJ, Scurlock AM, Zhang K, Bryceson YT, Bleesing J, Marsh RA (July 2018). "Screening for Wiskott-Aldrich syndrome by flow cytometry". J. Allergy Clin. Immunol. 142 (1): 333–335.e8. doi:10.1016/j.jaci.2018.04.017. PMID 29729304. Vancouver style error: initials (help)
↑ ^59.0 ^59.1 Giliani S, Fiorini M, Mella P, Candotti F, Schumacher RF, Wengler GS, Lalatta F, Fasth A, Badolato R, Ugazio AG, Albertini A, Notarangelo LD (January 1999). "Prenatal molecular diagnosis of Wiskott-Aldrich syndrome by direct mutation analysis". Prenat. Diagn. 19 (1): 36–40. PMID 10073904.
↑ ^60.0 ^60.1 Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA (December 1994). "A multiinstitutional survey of the Wiskott-Aldrich syndrome". J. Pediatr. 125 (6 Pt 1): 876–85. PMID 7996359.
↑ WEINTRAUB HD, WILSON WJ (August 1964). "PNEUMOCYSTIS CARINII PNEUMONIA IN WISKOTT-ALDRICH SYNDROME". Am. J. Dis. Child. 108: 198–200. PMID 14159941.
↑ Blancas-Galicia L, Escamilla-Quiroz C, Yamazaki-Nakashimada MA (2011). "[Wiskott-Aldrich Syndrome: An updated review]". Rev Alerg Mex (in Spanish; Castilian). 58 (4): 213–8. PMID 24007832.
↑ ^63.0 ^63.1 Imai K, Morio T, Zhu Y, Jin Y, Itoh S, Kajiwara M, Yata J, Mizutani S, Ochs HD, Nonoyama S (January 2004). "Clinical course of patients with WASP gene mutations". Blood. 103 (2): 456–64. doi:10.1182/blood-2003-05-1480. PMID 12969986.
↑ Notarangelo LD (February 2013). "In Wiskott-Aldrich syndrome, platelet count matters". Blood. 121 (9): 1484–5. doi:10.1182/blood-2013-01-475913. PMID 23449611.
↑ Dupuis-Girod S, Medioni J, Haddad E, Quartier P, Cavazzana-Calvo M, Le Deist F, de Saint Basile G, Delaunay J, Schwarz K, Casanova JL, Blanche S, Fischer A (May 2003). "Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients". Pediatrics. 111 (5 Pt 1): e622–7. PMID 12728121.
↑ Chen N, Zhang ZY, Liu DW, Liu W, Tang XM, Zhao XD (October 2015). "The clinical features of autoimmunity in 53 patients with Wiskott-Aldrich syndrome in China: a single-center study". Eur. J. Pediatr. 174 (10): 1311–8. doi:10.1007/s00431-015-2527-3. PMID 25877044.
↑ Ohya T, Yanagimachi M, Iwasawa K, Umetsu S, Sogo T, Inui A, Fujisawa T, Ito S (December 2017). "Childhood-onset inflammatory bowel diseases associated with mutation of Wiskott-Aldrich syndrome protein gene". World J. Gastroenterol. 23 (48): 8544–8552. doi:10.3748/wjg.v23.i48.8544. PMC 5752714. PMID 29358862.
↑ Cotelingam JD, Witebsky FG, Hsu SM, Blaese RM, Jaffe ES (1985). "Malignant lymphoma in patients with the Wiskott-Aldrich syndrome". Cancer Invest. 3 (6): 515–22. PMID 3910193.
↑ Yoshimi A, Kamachi Y, Imai K, Watanabe N, Nakadate H, Kanazawa T, Ozono S, Kobayashi R, Yoshida M, Kobayashi C, Hama A, Muramatsu H, Sasahara Y, Jakob M, Morio T, Ehl S, Manabe A, Niemeyer C, Kojima S (May 2013). "Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia". Pediatr Blood Cancer. 60 (5): 836–41. doi:10.1002/pbc.24359. PMID 23023736.
↑ Kobayashi R, Ariga T, Nonoyama S, Kanegane H, Tsuchiya S, Morio T, Yabe H, Nagatoshi Y, Kawa K, Tabuchi K, Tsuchida M, Miyawaki T, Kato S (November 2006). "Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan". Br. J. Haematol. 135 (3): 362–6. doi:10.1111/j.1365-2141.2006.06297.x. PMID 17032176.
↑ Jin Y, Mazza C, Christie JR, Giliani S, Fiorini M, Mella P, Gandellini F, Stewart DM, Zhu Q, Nelson DL, Notarangelo LD, Ochs HD (December 2004). "Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation". Blood. 104 (13): 4010–9. doi:10.1182/blood-2003-05-1592. PMID 15284122.
↑ Suri D, Singh S, Rawat A, Gupta A, Kamae C, Honma K, Nakagawa N, Imai K, Nonoyama S, Oshima K, Mitsuiki N, Ohara O, Bilhou-Nabera C, Proust A, Ahluwalia J, Dogra S, Saikia B, Minz RW, Sehgal S (March 2012). "Clinical profile and genetic basis of Wiskott-Aldrich syndrome at Chandigarh, North India". Asian Pac. J. Allergy Immunol. 30 (1): 71–8. PMID 22523910.
↑ De Bernardi A, Chessa Ricotti G, Galli L, Funis M (1990). "[Wiskott-Aldrich syndrome: description of a clinical case]". Pediatr Med Chir (in Italian). 12 (6): 691–3. PMID 2093894.
↑ Ochs HD, Slichter SJ, Harker LA, Von Behrens WE, Clark RA, Wedgwood RJ (February 1980). "The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets". Blood. 55 (2): 243–52. PMID 6444359.
↑ Buchbinder D, Nugent DJ, Fillipovich AH (2014). "Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments". Appl Clin Genet. 7: 55–66. doi:10.2147/TACG.S58444. PMC 4012343. PMID 24817816.
↑ Humblet-Baron S, Sather B, Anover S, Becker-Herman S, Kasprowicz DJ, Khim S, Nguyen T, Hudkins-Loya K, Alpers CE, Ziegler SF, Ochs H, Torgerson T, Campbell DJ, Rawlings DJ (February 2007). "Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis". J. Clin. Invest. 117 (2): 407–18. doi:10.1172/JCI29539. PMC 1764857. PMID 17218989.
↑ Orange JS, Ramesh N, Remold-O'Donnell E, Sasahara Y, Koopman L, Byrne M, Bonilla FA, Rosen FS, Geha RS, Strominger JL (August 2002). "Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses". Proc. Natl. Acad. Sci. U.S.A. 99 (17): 11351–6. doi:10.1073/pnas.162376099. PMC 123260. PMID 12177428.
↑ Wu EY, Ehrlich L, Handly B, Frush DP, Buckley RH (November 2016). "Clinical and imaging considerations in primary immunodeficiency disorders: an update". Pediatr Radiol. 46 (12): 1630–1644. doi:10.1007/s00247-016-3684-x. PMC 5083248. PMID 27655432.
↑ Litzman J, Jones A, Hann I, Chapel H, Strobel S, Morgan G (November 1996). "Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome". Arch. Dis. Child. 75 (5): 436–9. PMC 1511781. PMID 8957959.
↑ Kim KR, Kim JM, Kang JM, Kim YJ (June 2016). "Pneumocystis jirovecii pneumonia in pediatric patients: an analysis of 15 confirmed consecutive cases during 14 years". Korean J Pediatr. 59 (6): 252–5. doi:10.3345/kjp.2016.59.6.252. PMC 4958702. PMID 27462353.
↑ Modiano P, Salloum E, Gillet-Terver MN, Barbaud A, Georges JC, Thouvenot D, Schmutz JL, Weber M (September 1995). "Acyclovir-resistant chronic cutaneous herpes simplex in Wiskott-Aldrich syndrome". Br. J. Dermatol. 133 (3): 475–8. PMID 8547009.
↑ Ferrara M, Capozzi L, Coppola A, Save G, Coppola L (August 2007). "Prophylactic platelet transfusion in children with thrombocytopenic disorders: a retrospective review". Hematology. 12 (4): 297–9. doi:10.1080/10245330701255213. PMID 17654055.
↑ Blaese RM, Strober W, Levy AL, Waldmann TA (November 1971). "Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome. A unique disorder of serum protein metabolism". J. Clin. Invest. 50 (11): 2331–8. doi:10.1172/JCI106731. PMC 292175. PMID 5096517.
↑ Kim JJ, Thrasher AJ, Jones AM, Davies EG, Cale CM (July 2007). "Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency". Br. J. Haematol. 138 (1): 94–6. doi:10.1111/j.1365-2141.2007.06616.x. PMID 17498197.
↑ Gerrits AJ, Leven EA, Frelinger AL, Brigstocke SL, Berny-Lang MA, Mitchell WB, Revel-Vilk S, Tamary H, Carmichael SL, Barnard MR, Michelson AD, Bussel JB (September 2015). "Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia". Blood. 126 (11): 1367–78. doi:10.1182/blood-2014-09-602573. PMC 4729539. PMID 26224646.
↑ Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Díez IA, Dewey RA, Böhm M, Nowrouzi A, Ball CR, Glimm H, Naundorf S, Kühlcke K, Blasczyk R, Kondratenko I, Maródi L, Orange JS, von Kalle C, Klein C (November 2010). "Stem-cell gene therapy for the Wiskott-Aldrich syndrome". N. Engl. J. Med. 363 (20): 1918–27. doi:10.1056/NEJMoa1003548. PMC 3064520. PMID 21067383.
↑ Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM (December 1968). "Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome". Lancet. 2 (7583): 1364–6. PMID 4177931.
↑ Antoine C, Müller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, Fasth A, Heilmann C, Wulffraat N, Seger R, Blanche S, Friedrich W, Abinun M, Davies G, Bredius R, Schulz A, Landais P, Fischer A (February 2003). "Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99". Lancet. 361 (9357): 553–60. PMID 12598139.
↑ Muñoz A, Olivé T, Martinez A, Bureo E, Maldonado MS, Diaz de Heredia C, Sastre A, Gonzalez-Vicent M (September 2007). "Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON)". Pediatr Hematol Oncol. 24 (6): 393–402. doi:10.1080/08880010701454404. PMID 17710656.
↑ Lum LG, Tubergen DG, Corash L, Blaese RM (April 1980). "Splenectomy in the management of the thrombocytopenia of the Wiskott-Aldrich syndrome". N. Engl. J. Med. 302 (16): 892–6. doi:10.1056/NEJM198004173021604. PMID 6767187.
↑ Syrigos KN, Makrilia N, Neidhart J, Moutsos M, Tsimpoukis S, Kiagia M, Saif MW (September 2011). "Prolonged survival after splenectomy in Wiskott-Aldrich syndrome: a case report". Ital J Pediatr. 37: 42. doi:10.1186/1824-7288-37-42. PMC 3179709. PMID 21906397.
↑ Derry JM, Ochs HD, Francke U (August 1994). "Isolation of a novel gene mutated in Wiskott-Aldrich syndrome". Cell. 78 (4): 635–44. PMID 8069912.

Template:WikiDoc Sources

[Aldrich-1] Aldrich RA, Steinberg AG, Campbell DC (1954). "Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea". Pediatrics. 13 (2): 133–9. PMID 13133561.

[2] Wiskott, A (1937). "Familiärer, angeborener Morbus Werlhofii? ("Familial congenital Werlhof's disease?")". Montsschr Kinderheilkd. 68: 212–16.

[3] Binder V, Albert MH, Kabus M, Bertone M, Meindl A, Belohradsky BH (2006). "The genotype of the original Wiskott phenotype". N. Engl. J. Med. 355 (17): 1790–3. doi:10.1056/NEJMoa062520. PMID 17065640.

[Jin-4] Jin Y, Mazza C, Christie JR; et al. (2004). "Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation". Blood. 104 (13): 4010–9. doi:10.1182/blood-2003-05-1592. PMID 15284122.

[titleWiskott-Aldrich_Syndrome:_Immunodeficiency_Disorders:_Merck_Manual_Professional-5] 5.0 ^5.1 "Wiskott-Aldrich Syndrome: Immunodeficiency Disorders: Merck Manual Professional". Retrieved 2008-03-01.

[CD43_a_defective_molecule_in_Wiskott-Aldrich_syndrome-6] 6.0 ^6.1 PMID 1683685 (PMID 1683685)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand

[pmid17910333-7] Agarwal S, Cunningham-Rundles C (September 2007). "Assessment and clinical interpretation of reduced IgG values". Ann. Allergy Asthma Immunol. 99 (3): 281–3. doi:10.1016/S1081-1206(10)60665-5. PMC 3099256. PMID 17910333.

[pmid7679206-8] Korthäuer U, Graf D, Mages HW, Brière F, Padayachee M, Malcolm S, Ugazio AG, Notarangelo LD, Levinsky RJ, Kroczek RA (February 1993). "Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM". Nature. 361 (6412): 539–41. doi:10.1038/361539a0. PMID 7679206.

[pmid9255191-9] Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, Resnick I, Fasth A, Baer M, Gomez L, Sanders EA, Tabone MD, Plantaz D, Etzioni A, Monafo V, Abinun M, Hammarstrom L, Abrahamsen T, Jones A, Finn A, Klemola T, DeVries E, Sanal O, Peitsch MC, Notarangelo LD (July 1997). "Clinical spectrum of X-linked hyper-IgM syndrome". J. Pediatr. 131 (1 Pt 1): 47–54. PMID 9255191.

[pmid14663287-10] Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, Stiehm ER, Conley ME (November 2003). "The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients". Medicine (Baltimore). 82 (6): 373–84. doi:10.1097/01.md.0000100046.06009.b0. PMID 14663287.

[pmid10352287-11] Subauste CS, Wessendarp M, Sorensen RU, Leiva LE (June 1999). "CD40-CD40 ligand interaction is central to cell-mediated immunity against Toxoplasma gondii: patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimer". J. Immunol. 162 (11): 6690–700. PMID 10352287.

[pmid8993019-12] Hayward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A, Bonnefoy JY, Cosyns M, Weinberg A (January 1997). "Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM". J. Immunol. 158 (2): 977–83. PMID 8993019.

[pmid20180797-13] Davies EG, Thrasher AJ (April 2010). "Update on the hyper immunoglobulin M syndromes". Br. J. Haematol. 149 (2): 167–80. doi:10.1111/j.1365-2141.2010.08077.x. PMC 2855828. PMID 20180797.

[pmid20101521-14] Yel L (January 2010). "Selective IgA deficiency". J. Clin. Immunol. 30 (1): 10–6. doi:10.1007/s10875-009-9357-x. PMC 2821513. PMID 20101521.

[pmid19153537-15] Suzuki H, Kaneko H, Fukao T, Jin R, Kawamoto N, Asano T, Matsui E, Kasahara K, Kondo N (March 2009). "Various expression patterns of alpha1 and alpha2 genes in IgA deficiency". Allergol Int. 58 (1): 111–7. doi:10.2332/allergolint.O-08-549. PMID 19153537.

[pmid11720003-16] Cunningham-Rundles C (September 2001). "Physiology of IgA and IgA deficiency". J. Clin. Immunol. 21 (5): 303–9. PMID 11720003.

[pmid15093556-17] Edwards E, Razvi S, Cunningham-Rundles C (April 2004). "IgA deficiency: clinical correlates and responses to pneumococcal vaccine". Clin. Immunol. 111 (1): 93–7. doi:10.1016/j.clim.2003.12.005. PMID 15093556.

[pmid305332-18] Chipps BE, Talamo RC, Winkelstein JA (April 1978). "IgA deficiency, recurrent pneumonias, and bronchiectasis". Chest. 73 (4): 519–26. PMID 305332.

[pmid5056860-19] Zinneman HH, Kaplan AP (September 1972). "The association of giardiasis with reduced intestinal secretory immunoglobulin A". Am J Dig Dis. 17 (9): 793–7. PMID 5056860.

[pmid18683032-20] Aghamohammadi A, Cheraghi T, Gharagozlou M, Movahedi M, Rezaei N, Yeganeh M, Parvaneh N, Abolhassani H, Pourpak Z, Moin M (January 2009). "IgA deficiency: correlation between clinical and immunological phenotypes". J. Clin. Immunol. 29 (1): 130–6. doi:10.1007/s10875-008-9229-9. PMID 18683032.

[pmid19541543-21] Janzi M, Kull I, Sjöberg R, Wan J, Melén E, Bayat N, Ostblom E, Pan-Hammarström Q, Nilsson P, Hammarström L (October 2009). "Selective IgA deficiency in early life: association to infections and allergic diseases during childhood". Clin. Immunol. 133 (1): 78–85. doi:10.1016/j.clim.2009.05.014. PMID 19541543.

[pmid18202833-22] Jacob CM, Pastorino AC, Fahl K, Carneiro-Sampaio M, Monteiro RC (May 2008). "Autoimmunity in IgA deficiency: revisiting the role of IgA as a silent housekeeper". J. Clin. Immunol. 28 Suppl 1: S56–61. doi:10.1007/s10875-007-9163-2. PMID 18202833.

[pmid10600329-23] Conley ME, Notarangelo LD, Etzioni A (December 1999). "Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies)". Clin. Immunol. 93 (3): 190–7. doi:10.1006/clim.1999.4799. PMID 10600329.

[pmid4012343-24] Mayer RJ, Schiffer CA, Peterson BA, Silver RT, Cornwell GG, McIntyre OR, Rai KR, Budman DR, Ellison RR, Maguire M (June 1985). "Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I study". Semin. Oncol. 12 (2 Suppl 3): 84–90. PMID 4012343.

[pmid23527602-25] Massaad MJ, Ramesh N, Geha RS (May 2013). "Wiskott-Aldrich syndrome: a comprehensive review". Ann. N. Y. Acad. Sci. 1285: 26–43. doi:10.1111/nyas.12049. PMID 23527602.

[pmid29086100-26] Candotti F (January 2018). "Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome". J. Clin. Immunol. 38 (1): 13–27. doi:10.1007/s10875-017-0453-z. PMID 29086100.

[pmid28851742-27] Sereni L, Castiello MC, Villa A (March 2018). "Platelets in Wiskott-Aldrich syndrome: Victims or executioners?". J. Leukoc. Biol. 103 (3): 577–590. doi:10.1189/jlb.5MR0617-257R. PMID 28851742.

[pmid21178275-28] Blundell MP, Worth A, Bouma G, Thrasher AJ (2010). "The Wiskott-Aldrich syndrome: The actin cytoskeleton and immune cell function". Dis. Markers. 29 (3–4): 157–75. doi:10.3233/DMA-2010-0735. PMC 3835520. PMID 21178275.

[pmid19351959-29] Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia Roncarolo M (June 2009). "Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome". Blood. 113 (25): 6288–95. doi:10.1182/blood-2008-12-115253. PMID 19351959.

[pmid11091267-30] 30.0 ^30.1 Fischer A (November 2000). "Severe combined immunodeficiencies (SCID)". Clin. Exp. Immunol. 122 (2): 143–9. PMC 1905779. PMID 11091267.

[pmid8462096-31] Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, McBride OW, Leonard WJ (April 1993). "Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans". Cell. 73 (1): 147–57. PMID 8462096.

[pmid8961626-32] Puck JM (November 1996). "IL2RGbase: a database of gamma c-chain defects causing human X-SCID". Immunol. Today. 17 (11): 507–11. PMID 8961626.

[pmid104530-33] Rowiński J, Souchier C, Czyba JC (1978). "DNA content of cells in human buccal smears. A preliminary study". Acta Histochem. 62 (2): 276–81. doi:10.1016/S0065-1281(78)80093-2. PMID 104530.

[pmid3436096-34] Morgan G, Levinsky RJ, Hugh-Jones K, Fairbanks LD, Morris GS, Simmonds HA (December 1987). "Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency". Clin. Exp. Immunol. 70 (3): 491–9. PMC 1542189. PMID 3436096.

[pmid7401839-35] Ballard RW, Cummings CW (August 1980). "Job's syndrome". Laryngoscope. 90 (8 Pt 1): 1367–70. PMID 7401839.

[pmid18424333-36] Freeman AF, Holland SM (May 2008). "The hyper-IgE syndromes". Immunol Allergy Clin North Am. 28 (2): 277–91, viii. doi:10.1016/j.iac.2008.01.005. PMC 2683262. PMID 18424333.

[pmid17881745-37] Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, Freeman AF, Demidowich A, Davis J, Turner ML, Anderson VL, Darnell DN, Welch PA, Kuhns DB, Frucht DM, Malech HL, Gallin JI, Kobayashi SD, Whitney AR, Voyich JM, Musser JM, Woellner C, Schäffer AA, Puck JM, Grimbacher B (October 2007). "STAT3 mutations in the hyper-IgE syndrome". N. Engl. J. Med. 357 (16): 1608–19. doi:10.1056/NEJMoa073687. PMID 17881745.

[pmid17098478-38] Ling JC, Freeman AF, Gharib AM, Arai AE, Lederman RJ, Rosing DR, Holland SM (March 2007). "Coronary artery aneurysms in patients with hyper IgE recurrent infection syndrome". Clin. Immunol. 122 (3): 255–8. doi:10.1016/j.clim.2006.10.005. PMID 17098478.

[pmid3338649-39] Hutto JO, Bryan CS, Greene FL, White CJ, Gallin JI (March 1988). "Cryptococcosis of the colon resembling Crohn's disease in a patient with the hyperimmunoglobulinemia E-recurrent infection (Job's) syndrome". Gastroenterology. 94 (3): 808–12. PMID 3338649.

[pmid10673653-40] O'Connell AC, Puck JM, Grimbacher B, Facchetti F, Majorana A, Gallin JI, Malech HL, Holland SM (February 2000). "Delayed eruption of permanent teeth in hyperimmunoglobulinemia E recurrent infection syndrome". Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 89 (2): 177–85. doi:10.1067/moe.2000.103129. PMID 10673653.

[pmid23883805-41] Tam JS, Routes JM (2013). "Common variable immunodeficiency". Am J Rhinol Allergy. 27 (4): 260–5. doi:10.2500/ajra.2013.27.3899. PMC 3901442. PMID 23883805.

[pmid22180439-42] Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C (February 2012). "Morbidity and mortality in common variable immune deficiency over 4 decades". Blood. 119 (7): 1650–7. doi:10.1182/blood-2011-09-377945. PMC 3286343. PMID 22180439.

[pmid18419489-43] Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, Viallard JF, Gardembas M, Galicier L, Schleinitz N, Suarez F, Soulas-Sprauel P, Hachulla E, Jaccard A, Gardeur A, Théodorou I, Rabian C, Debré P (May 2008). "Infections in 252 patients with common variable immunodeficiency". Clin. Infect. Dis. 46 (10): 1547–54. doi:10.1086/587669. PMID 18419489.

[pmid3963038-44] Roifman CM, Rao CP, Lederman HM, Lavi S, Quinn P, Gelfand EW (April 1986). "Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia". Am. J. Med. 80 (4): 590–4. PMID 3963038.

[pmid21970952-45] Yong PF, Thaventhiran JE, Grimbacher B (2011). ""A rose is a rose is a rose," but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011?". Adv. Immunol. 111: 47–107. doi:10.1016/B978-0-12-385991-4.00002-7. PMID 21970952.

[pmid16007087-46] Salzer U, Chapel HM, Webster AD, Pan-Hammarström Q, Schmitt-Graeff A, Schlesier M, Peter HH, Rockstroh JK, Schneider P, Schäffer AA, Hammarström L, Grimbacher B (August 2005). "Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans". Nat. Genet. 37 (8): 820–8. doi:10.1038/ng1600. PMID 16007087.

[pmid17510807-47] Quinti I, Soresina A, Spadaro G, Martino S, Donnanno S, Agostini C, Claudio P, Franco D, Maria Pesce A, Borghese F, Guerra A, Rondelli R, Plebani A (May 2007). "Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency". J. Clin. Immunol. 27 (3): 308–16. doi:10.1007/s10875-007-9075-1. PMID 17510807.

[pmid26564081-48] Nissenkorn A, Ben-Zeev B (2015). "Ataxia telangiectasia". Handb Clin Neurol. 132: 199–214. doi:10.1016/B978-0-444-62702-5.00014-7. PMID 26564081.

[pmid27884168-49] Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM (November 2016). "Ataxia telangiectasia: a review". Orphanet J Rare Dis. 11 (1): 159. doi:10.1186/s13023-016-0543-7. PMC 5123280. PMID 27884168.

[pmid9874856-50] Crawford TO (December 1998). "Ataxia telangiectasia". Semin Pediatr Neurol. 5 (4): 287–94. PMID 9874856.

[pmid2415689-51] Boder E (1985). "Ataxia-telangiectasia: an overview". Kroc Found Ser. 19: 1–63. PMID 2415689.

[pmid22614068-52] Hoche F, Seidel K, Theis M, Vlaho S, Schubert R, Zielen S, Kieslich M (June 2012). "Neurodegeneration in ataxia telangiectasia: what is new? What is evident?". Neuropediatrics. 43 (3): 119–29. doi:10.1055/s-0032-1313915. PMID 22614068.

[pmid13542097-53] BODER E, SEDGWICK RP (April 1958). "Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection". Pediatrics. 21 (4): 526–54. PMID 13542097.

[pmid24683014-54] Sahama I, Sinclair K, Pannek K, Lavin M, Rose S (August 2014). "Radiological imaging in ataxia telangiectasia: a review". Cerebellum. 13 (4): 521–30. doi:10.1007/s12311-014-0557-4. PMID 24683014.

[pmid23886747-55] Lin DD, Barker PB, Lederman HM, Crawford TO (January 2014). "Cerebral abnormalities in adults with ataxia-telangiectasia". AJNR Am J Neuroradiol. 35 (1): 119–23. doi:10.3174/ajnr.A3646. PMC 4106125. PMID 23886747.

[pmid15069401-56] Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, Carson KA, Lederman HM (April 2004). "Immunodeficiency and infections in ataxia-telangiectasia". J. Pediatr. 144 (4): 505–11. doi:10.1016/j.jpeds.2003.12.046. PMID 15069401.

[pmid28966616-57] ↑

[pmid29729304-58] Chiang S, Vergamini SM, Husami A, Neumeier L, Quinn K, Ellerhorst T, Sheppard L, Gifford C, Buchbinder D, Joshi A, Ifversen M, Kleiner GI, Bussel JB, Chandrakasan S, Pesek RD, Pozos TC, Rose MJ, Scurlock AM, Zhang K, Bryceson YT, Bleesing J, Marsh RA (July 2018). "Screening for Wiskott-Aldrich syndrome by flow cytometry". J. Allergy Clin. Immunol. 142 (1): 333–335.e8. doi:10.1016/j.jaci.2018.04.017. PMID 29729304. Vancouver style error: initials (help)

[pmid10073904-59] 59.0 ^59.1 Giliani S, Fiorini M, Mella P, Candotti F, Schumacher RF, Wengler GS, Lalatta F, Fasth A, Badolato R, Ugazio AG, Albertini A, Notarangelo LD (January 1999). "Prenatal molecular diagnosis of Wiskott-Aldrich syndrome by direct mutation analysis". Prenat. Diagn. 19 (1): 36–40. PMID 10073904.

[pmid7996359-60] 60.0 ^60.1 Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA (December 1994). "A multiinstitutional survey of the Wiskott-Aldrich syndrome". J. Pediatr. 125 (6 Pt 1): 876–85. PMID 7996359.

[pmid14159941-61] WEINTRAUB HD, WILSON WJ (August 1964). "PNEUMOCYSTIS CARINII PNEUMONIA IN WISKOTT-ALDRICH SYNDROME". Am. J. Dis. Child. 108: 198–200. PMID 14159941.

[pmid24007832-62] Blancas-Galicia L, Escamilla-Quiroz C, Yamazaki-Nakashimada MA (2011). "[Wiskott-Aldrich Syndrome: An updated review]". Rev Alerg Mex (in Spanish; Castilian). 58 (4): 213–8. PMID 24007832.

[pmid12969986-63] 63.0 ^63.1 Imai K, Morio T, Zhu Y, Jin Y, Itoh S, Kajiwara M, Yata J, Mizutani S, Ochs HD, Nonoyama S (January 2004). "Clinical course of patients with WASP gene mutations". Blood. 103 (2): 456–64. doi:10.1182/blood-2003-05-1480. PMID 12969986.

[pmid23449611-64] Notarangelo LD (February 2013). "In Wiskott-Aldrich syndrome, platelet count matters". Blood. 121 (9): 1484–5. doi:10.1182/blood-2013-01-475913. PMID 23449611.

[pmid12728121-65] Dupuis-Girod S, Medioni J, Haddad E, Quartier P, Cavazzana-Calvo M, Le Deist F, de Saint Basile G, Delaunay J, Schwarz K, Casanova JL, Blanche S, Fischer A (May 2003). "Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients". Pediatrics. 111 (5 Pt 1): e622–7. PMID 12728121.

[pmid25877044-66] Chen N, Zhang ZY, Liu DW, Liu W, Tang XM, Zhao XD (October 2015). "The clinical features of autoimmunity in 53 patients with Wiskott-Aldrich syndrome in China: a single-center study". Eur. J. Pediatr. 174 (10): 1311–8. doi:10.1007/s00431-015-2527-3. PMID 25877044.

[pmid29358862-67] Ohya T, Yanagimachi M, Iwasawa K, Umetsu S, Sogo T, Inui A, Fujisawa T, Ito S (December 2017). "Childhood-onset inflammatory bowel diseases associated with mutation of Wiskott-Aldrich syndrome protein gene". World J. Gastroenterol. 23 (48): 8544–8552. doi:10.3748/wjg.v23.i48.8544. PMC 5752714. PMID 29358862.

[pmid3910193-68] Cotelingam JD, Witebsky FG, Hsu SM, Blaese RM, Jaffe ES (1985). "Malignant lymphoma in patients with the Wiskott-Aldrich syndrome". Cancer Invest. 3 (6): 515–22. PMID 3910193.

[pmid23023736-69] Yoshimi A, Kamachi Y, Imai K, Watanabe N, Nakadate H, Kanazawa T, Ozono S, Kobayashi R, Yoshida M, Kobayashi C, Hama A, Muramatsu H, Sasahara Y, Jakob M, Morio T, Ehl S, Manabe A, Niemeyer C, Kojima S (May 2013). "Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia". Pediatr Blood Cancer. 60 (5): 836–41. doi:10.1002/pbc.24359. PMID 23023736.

[pmid17032176-70] Kobayashi R, Ariga T, Nonoyama S, Kanegane H, Tsuchiya S, Morio T, Yabe H, Nagatoshi Y, Kawa K, Tabuchi K, Tsuchida M, Miyawaki T, Kato S (November 2006). "Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan". Br. J. Haematol. 135 (3): 362–6. doi:10.1111/j.1365-2141.2006.06297.x. PMID 17032176.

[pmid15284122-71] Jin Y, Mazza C, Christie JR, Giliani S, Fiorini M, Mella P, Gandellini F, Stewart DM, Zhu Q, Nelson DL, Notarangelo LD, Ochs HD (December 2004). "Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation". Blood. 104 (13): 4010–9. doi:10.1182/blood-2003-05-1592. PMID 15284122.

[pmid22523910-72] Suri D, Singh S, Rawat A, Gupta A, Kamae C, Honma K, Nakagawa N, Imai K, Nonoyama S, Oshima K, Mitsuiki N, Ohara O, Bilhou-Nabera C, Proust A, Ahluwalia J, Dogra S, Saikia B, Minz RW, Sehgal S (March 2012). "Clinical profile and genetic basis of Wiskott-Aldrich syndrome at Chandigarh, North India". Asian Pac. J. Allergy Immunol. 30 (1): 71–8. PMID 22523910.

[pmid2093894-73] De Bernardi A, Chessa Ricotti G, Galli L, Funis M (1990). "[Wiskott-Aldrich syndrome: description of a clinical case]". Pediatr Med Chir (in Italian). 12 (6): 691–3. PMID 2093894.

[pmid6444359-74] Ochs HD, Slichter SJ, Harker LA, Von Behrens WE, Clark RA, Wedgwood RJ (February 1980). "The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets". Blood. 55 (2): 243–52. PMID 6444359.

[pmid24817816-75] Buchbinder D, Nugent DJ, Fillipovich AH (2014). "Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments". Appl Clin Genet. 7: 55–66. doi:10.2147/TACG.S58444. PMC 4012343. PMID 24817816.

[pmid17218989-76] Humblet-Baron S, Sather B, Anover S, Becker-Herman S, Kasprowicz DJ, Khim S, Nguyen T, Hudkins-Loya K, Alpers CE, Ziegler SF, Ochs H, Torgerson T, Campbell DJ, Rawlings DJ (February 2007). "Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis". J. Clin. Invest. 117 (2): 407–18. doi:10.1172/JCI29539. PMC 1764857. PMID 17218989.

[pmid12177428-77] Orange JS, Ramesh N, Remold-O'Donnell E, Sasahara Y, Koopman L, Byrne M, Bonilla FA, Rosen FS, Geha RS, Strominger JL (August 2002). "Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses". Proc. Natl. Acad. Sci. U.S.A. 99 (17): 11351–6. doi:10.1073/pnas.162376099. PMC 123260. PMID 12177428.

[pmid27655432-78] Wu EY, Ehrlich L, Handly B, Frush DP, Buckley RH (November 2016). "Clinical and imaging considerations in primary immunodeficiency disorders: an update". Pediatr Radiol. 46 (12): 1630–1644. doi:10.1007/s00247-016-3684-x. PMC 5083248. PMID 27655432.

[pmid8957959-79] Litzman J, Jones A, Hann I, Chapel H, Strobel S, Morgan G (November 1996). "Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome". Arch. Dis. Child. 75 (5): 436–9. PMC 1511781. PMID 8957959.

[pmid27462353-80] Kim KR, Kim JM, Kang JM, Kim YJ (June 2016). "Pneumocystis jirovecii pneumonia in pediatric patients: an analysis of 15 confirmed consecutive cases during 14 years". Korean J Pediatr. 59 (6): 252–5. doi:10.3345/kjp.2016.59.6.252. PMC 4958702. PMID 27462353.

[pmid8547009-81] Modiano P, Salloum E, Gillet-Terver MN, Barbaud A, Georges JC, Thouvenot D, Schmutz JL, Weber M (September 1995). "Acyclovir-resistant chronic cutaneous herpes simplex in Wiskott-Aldrich syndrome". Br. J. Dermatol. 133 (3): 475–8. PMID 8547009.

[pmid17654055-82] Ferrara M, Capozzi L, Coppola A, Save G, Coppola L (August 2007). "Prophylactic platelet transfusion in children with thrombocytopenic disorders: a retrospective review". Hematology. 12 (4): 297–9. doi:10.1080/10245330701255213. PMID 17654055.

[pmid5096517-83] Blaese RM, Strober W, Levy AL, Waldmann TA (November 1971). "Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome. A unique disorder of serum protein metabolism". J. Clin. Invest. 50 (11): 2331–8. doi:10.1172/JCI106731. PMC 292175. PMID 5096517.

[pmid17498197-84] Kim JJ, Thrasher AJ, Jones AM, Davies EG, Cale CM (July 2007). "Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency". Br. J. Haematol. 138 (1): 94–6. doi:10.1111/j.1365-2141.2007.06616.x. PMID 17498197.

[pmid26224646-85] Gerrits AJ, Leven EA, Frelinger AL, Brigstocke SL, Berny-Lang MA, Mitchell WB, Revel-Vilk S, Tamary H, Carmichael SL, Barnard MR, Michelson AD, Bussel JB (September 2015). "Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia". Blood. 126 (11): 1367–78. doi:10.1182/blood-2014-09-602573. PMC 4729539. PMID 26224646.

[pmid21067383-86] Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Díez IA, Dewey RA, Böhm M, Nowrouzi A, Ball CR, Glimm H, Naundorf S, Kühlcke K, Blasczyk R, Kondratenko I, Maródi L, Orange JS, von Kalle C, Klein C (November 2010). "Stem-cell gene therapy for the Wiskott-Aldrich syndrome". N. Engl. J. Med. 363 (20): 1918–27. doi:10.1056/NEJMoa1003548. PMC 3064520. PMID 21067383.

[pmid4177931-87] Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM (December 1968). "Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome". Lancet. 2 (7583): 1364–6. PMID 4177931.

[pmid12598139-88] Antoine C, Müller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, Fasth A, Heilmann C, Wulffraat N, Seger R, Blanche S, Friedrich W, Abinun M, Davies G, Bredius R, Schulz A, Landais P, Fischer A (February 2003). "Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99". Lancet. 361 (9357): 553–60. PMID 12598139.

[pmid17710656-89] Muñoz A, Olivé T, Martinez A, Bureo E, Maldonado MS, Diaz de Heredia C, Sastre A, Gonzalez-Vicent M (September 2007). "Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON)". Pediatr Hematol Oncol. 24 (6): 393–402. doi:10.1080/08880010701454404. PMID 17710656.

[pmid6767187-90] Lum LG, Tubergen DG, Corash L, Blaese RM (April 1980). "Splenectomy in the management of the thrombocytopenia of the Wiskott-Aldrich syndrome". N. Engl. J. Med. 302 (16): 892–6. doi:10.1056/NEJM198004173021604. PMID 6767187.

[pmid21906397-91] Syrigos KN, Makrilia N, Neidhart J, Moutsos M, Tsimpoukis S, Kiagia M, Saif MW (September 2011). "Prolonged survival after splenectomy in Wiskott-Aldrich syndrome: a case report". Ital J Pediatr. 37: 42. doi:10.1186/1824-7288-37-42. PMC 3179709. PMID 21906397.

[pmid8069912-92] Derry JM, Ochs HD, Francke U (August 1994). "Isolation of a novel gene mutated in Wiskott-Aldrich syndrome". Cell. 78 (4): 635–44. PMID 8069912.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

[29]

[30]

[31]

[32]

[33]

[34]

[35]

[36]

[37]

[38]

[39]

[40]

[41]

[42]

[43]

[44]

[45]

[46]

[47]

[48]

[49]

[50]

[51]

[52]

[53]

[54]

[55]

[56]

[57]

[58]

[59]

[60]

[61]

[62]

[63]

[64]

[65]

[66]

[67]

[68]

[69]

[70]

[71]

[72]

[73]

[74]

[75]

[76]

[77]

[78]

[79]

[80]

[81]

[82]

[83]

[84]

[85]

[86]

[87]

[88]

[89]

[90]

[91]

[92]

@@ Line 1: / Line 1: @@
 __NOTOC__
-{{Infobox_Disease |
+{{SI}}
-  Name           = {{PAGENAME}} |
-  Image          = |
-  Caption        = |
-  DiseasesDB     = 14176 |
-  ICD10          = {{ICD10|D|82|0|d|80}} |
-  ICD9           = {{ICD9|279.12}} |
-  ICDO           = |
-  OMIM           = 301000 |
-  MedlinePlus    = |
-  MeshID         = D014923 |
-}}
-{{Wiskott-Aldrich syndrome}}
-{{CMG}}
-'''Associate Editor-In-Chief:''' {{CZ}}
+{{CMG}}; {{AE}} {{CK}}; {{HK}}; {{CZ}}
-==[[Wiskott-Aldrich syndrome overview|Overview]]==
+{{SK}} Aldrich syndrome
-==[[Wiskott-Aldrich syndrome historical perspective|Historical Perspective]]==
+==Overview==
+'''Wiskott-Aldrich syndrome''' (WAS) is a rare [[sex-linked|X-linked]] [[recessive gene|recessive]] disease characterized by [[eczema]], [[thrombocytopenia]] (low [[platelet]] counts), [[immune deficiency]], and bloody diarrhea (due to the low platelet counts).  It is also sometimes called the ''eczema-thrombocytopenia-immunodeficiency syndrome'' in keeping with Aldrich's original description in 1954.<ref name="Aldrich">{{cite journal |author=Aldrich RA, Steinberg AG, Campbell DC |title=Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea |journal=Pediatrics |volume=13 |issue=2 |pages=133-9 |year=1954 |pmid=13133561}}</ref> The WAS-related disorders of X-linked thrombocytopenia (XLT) and X-linked congenital neutropenia (XLN) may present similar but less severe symptoms and are caused by mutations of the same gene.
-==[[Wiskott-Aldrich syndrome classification|Classification]]==
+==Historical Perspective==
+The syndrome is named after Dr Robert Anderson Aldrich, an American pediatrician who described the disease in a family of Dutch-Americans in 1954, and Dr Alfred Wiskott, a German pediatrician who first noticed the syndrome in 1937.<ref>{{cite journal |last=Wiskott |first=A |year=1937 |month= |title=''Famili&auml;rer, angeborener Morbus Werlhofii?'' ("Familial congenital Werlhof's disease?") |journal=Montsschr Kinderheilkd |volume=68 |issue= |pages=212-16}}</ref> Wiskott described three brothers with a similar disease, whose sisters were unaffected. In 2006 a German research group analysed family members of Wiskott's three cases, and surmised that they probably shared a novel frameshift mutation of the first exon of the ''WAS'' gene.<ref>{{cite journal |author=Binder V, Albert MH, Kabus M, Bertone M, Meindl A, Belohradsky BH |title=The genotype of the original Wiskott phenotype |journal=N. Engl. J. Med. |volume=355 |issue=17 |pages=1790-3 |year=2006 |pmid=17065640 |doi=10.1056/NEJMoa062520}}</ref>
-==[[Wiskott-Aldrich syndrome pathophysiology|Pathophysiology]]==
+==Classification==
+Jin et al (2004) employ a numerical grading of severity:<ref name="Jin">{{cite journal |author=Jin Y, Mazza C, Christie JR, ''et al'' |title=Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation |journal=Blood |volume=104 |issue=13 |pages=4010-9 |year=2004 |pmid=15284122 |doi=10.1182/blood-2003-05-1592}}</ref>
+* Grade 0.5: intermittent [[Thrombocytopenia|thrombopenia]]
+* Grade 1.0: [[Thrombocytopenia|thrombopenia]] and small platelets
+* Grade 2.0: [[Thrombocytopenia|thrombopenia]] and normally responsive [[eczema]] or occasional upper [[Respiratory tract infection|respiratory tract infections]].
+* Grade 2.5: [[Thrombocytopenia|thrombopenia]] and therapy-responsive but severe [[eczema]] or airway infections requiring antibiotics
+* Grade 3.0: both [[eczema]] ''and'' airway infections requiring antibiotics
+* Grade 4.0: [[eczema]] continuously requiring therapy and/or severe or life threatening infections
+* Grade 5.0: [[Autoimmunity|autoimmune]] disease or [[malignancy]] in an XLT/WAS patient.
-==[[Wiskott-Aldrich syndrome causes|Causes]]==
+==Pathophysiology==
+In the Wiskott–Aldrich syndrome, the [[Platelet|platelets]] are small and do not function properly. They are removed by the [[spleen]], which leads to low [[platelet]] counts.
-==[[Wiskott-Aldrich syndrome differential diagnosis|Differentiating Wiskott-Aldrich syndrome from other Diseases]]==
+Wiskott–Aldrich syndrome was linked in 1994 to mutations in a [[gene]] on the short arm of the [[X chromosome]], which was termed ''[[Wiskott-Aldrich syndrome protein]]'' (''WASp''). It was later discovered that the disease X-linked [[thrombocytopenia]] (XLT) was also due to ''WASp'' [[Mutation|mutations]], but different ones from those that cause full-blown Wiskott–Aldrich syndrome. Furthermore, the rare disorder X-linked [[neutropenia]] has been linked to particular mutations of the ''WASp'' gene.
-==[[Wiskott-Aldrich syndrome epidemiology and demographics|Epidemiology and Demographics]]==
+The ''WASp'' gene codes for the protein by the same name, which is 502 [[amino acid]]s long and is mainly expressed in [[haematopoeisis|hematopoietic]] cells (the cells in the bone marrow that develop into blood cells). The main function of WASp is to activate actin polymerization by binding to the [[Arp2/3 complex]].  In T-cell, WASp is important because it is known to be activated via [[T-cell receptor]] (TCR) signaling pathways to induce cortical actin [[cytoskeleton]] rearrangements that are responsible for forming the [[immunological synapse]].
-==[[Wiskott-Aldrich syndrome risk factors|Risk Factors]]==
+The immune deficiency is caused by decreased [[antibody]] production, and an inability for [[T cell]]s to become polarized <ref name="titleWiskott-Aldrich Syndrome: Immunodeficiency Disorders: Merck Manual Professional">{{cite web |url=http://www.merck.com/mmpe/sec13/ch164/ch164n.html |title=Wiskott-Aldrich Syndrome: Immunodeficiency Disorders: Merck Manual Professional |accessdate=2008-03-01 |work=}}</ref> (making it a [[combined immunodeficiency]]). This leads to increased susceptibility to [[Infection|infections]], particularly of the [[Ear|ears]] and [[sinuses]]. T cells are unable to reorganize their actin [[cytoskeleton]]. The type of [[mutation]] to the ''WASp'' gene correlates significantly with the degree of severity: those that led to the production of a truncated protein caused significantly more symptoms than those with a [[missense mutation]] but a normal-length WASp. Although autoimmune disease and [[malignancy]] occur in both types of [[mutation]], those patients with truncated WASp carry a higher risk.
-==[[Wiskott-Aldrich syndrome screening|Screening]]==
+A defect in [[CD43]] molecule has been found to be associated in patients with Wiskott–Aldrich syndrome.<ref name="CD43 a defective molecule in Wiskott-Aldrich syndrome">{{cite pmid|1683685}}</ref>
-==[[Wiskott-Aldrich syndrome natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
+==Causes==
+In Wiskott–Aldrich syndrome, the [[Platelet|platelets]] are small and do not function properly. They are removed by the [[spleen]], which leads to low [[platelet]] counts.
+Wiskott–Aldrich syndrome was linked in 1994 to [[Mutation|mutations]] in a [[gene]] on the short arm of the [[X chromosome]], which was termed ''[[Wiskott-Aldrich syndrome protein]]'' (''WASp''). It was later discovered that the disease X-linked [[thrombocytopenia]] (XLT) was also due to ''WASp'' mutations, but different ones from those that cause full-blown Wiskott–Aldrich syndrome. Furthermore, the rare disorder X-linked [[neutropenia]] has been linked to particular mutations of the ''WASp'' gene.
+The ''WASp'' gene codes for the protein by the same name, which is 502 [[amino acid]]s long and is mainly expressed in [[haematopoeisis|hematopoietic]] cells (the cells in the bone marrow that develop into blood cells). The main function of WASp is to activate actin polymerization by binding to the [[Arp2/3 complex]].  In T-cell, WASp is important because it is known to be activated via [[T-cell receptor]] (TCR) signaling pathways to induce cortical actin [[cytoskeleton]] rearrangements that are responsible for forming the [[immunological synapse]].
+The immune deficiency is caused by decreased [[antibody]] production, and an inability for [[T cell]]s to become polarized <ref name="titleWiskott-Aldrich Syndrome: Immunodeficiency Disorders: Merck Manual Professional">{{cite web |url=http://www.merck.com/mmpe/sec13/ch164/ch164n.html |title=Wiskott-Aldrich Syndrome: Immunodeficiency Disorders: Merck Manual Professional |accessdate=2008-03-01 |work=}}</ref> (making it a [[combined immunodeficiency]]). This leads to increased susceptibility to infections, particularly of the [[Ear|ears]] and [[sinuses]]. [[T cell|T-cells]] are unable to reorganize their actin [[cytoskeleton]]. The type of [[mutation]] to the ''WASp'' gene correlates significantly with the degree of severity: those that led to the production of a truncated protein caused significantly more symptoms than those with a [[missense mutation]] but a normal-length WASp. Although [[Autoimmunity|autoimmune]] disease and [[malignancy]] occur in both types of [[mutation]], those patients with truncated WASp carry a higher risk.
+A defect in [[CD43]] molecule has been found to be associated in patients with Wiskott–Aldrich syndrome.<ref name="CD43 a defective molecule in Wiskott-Aldrich syndrome">{{cite pmid|1683685}}</ref>
+==Differentiating Wiskott-Aldrich Syndrome From Other Disorders of Humoral Imuunodeficiency==
+Wiskott-Aldrich Syndrome should be differentiated from other disorders leading to [[hypogammaglobulinemia]] and defects of [[humoral immunity]]. The following conditions may be considered as differentials:<ref name="pmid17910333">{{cite journal |vauthors=Agarwal S, Cunningham-Rundles C |title=Assessment and clinical interpretation of reduced IgG values |journal=Ann. Allergy Asthma Immunol. |volume=99 |issue=3 |pages=281–3 |date=September 2007 |pmid=17910333 |pmc=3099256 |doi=10.1016/S1081-1206(10)60665-5 |url=}}</ref><ref name="pmid7679206">{{cite journal |vauthors=Korthäuer U, Graf D, Mages HW, Brière F, Padayachee M, Malcolm S, Ugazio AG, Notarangelo LD, Levinsky RJ, Kroczek RA |title=Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM |journal=Nature |volume=361 |issue=6412 |pages=539–41 |date=February 1993 |pmid=7679206 |doi=10.1038/361539a0 |url=}}</ref><ref name="pmid9255191">{{cite journal |vauthors=Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, Resnick I, Fasth A, Baer M, Gomez L, Sanders EA, Tabone MD, Plantaz D, Etzioni A, Monafo V, Abinun M, Hammarstrom L, Abrahamsen T, Jones A, Finn A, Klemola T, DeVries E, Sanal O, Peitsch MC, Notarangelo LD |title=Clinical spectrum of X-linked hyper-IgM syndrome |journal=J. Pediatr. |volume=131 |issue=1 Pt 1 |pages=47–54 |date=July 1997 |pmid=9255191 |doi= |url=}}</ref><ref name="pmid14663287">{{cite journal |vauthors=Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, Stiehm ER, Conley ME |title=The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients |journal=Medicine (Baltimore) |volume=82 |issue=6 |pages=373–84 |date=November 2003 |pmid=14663287 |doi=10.1097/01.md.0000100046.06009.b0 |url=}}</ref><ref name="pmid10352287">{{cite journal |vauthors=Subauste CS, Wessendarp M, Sorensen RU, Leiva LE |title=CD40-CD40 ligand interaction is central to cell-mediated immunity against Toxoplasma gondii: patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimer |journal=J. Immunol. |volume=162 |issue=11 |pages=6690–700 |date=June 1999 |pmid=10352287 |doi= |url=}}</ref><ref name="pmid8993019">{{cite journal |vauthors=Hayward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A, Bonnefoy JY, Cosyns M, Weinberg A |title=Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM |journal=J. Immunol. |volume=158 |issue=2 |pages=977–83 |date=January 1997 |pmid=8993019 |doi= |url=}}</ref><ref name="pmid20180797">{{cite journal |vauthors=Davies EG, Thrasher AJ |title=Update on the hyper immunoglobulin M syndromes |journal=Br. J. Haematol. |volume=149 |issue=2 |pages=167–80 |date=April 2010 |pmid=20180797 |pmc=2855828 |doi=10.1111/j.1365-2141.2010.08077.x |url=}}</ref><ref name="pmid20101521">{{cite journal |vauthors=Yel L |title=Selective IgA deficiency |journal=J. Clin. Immunol. |volume=30 |issue=1 |pages=10–6 |date=January 2010 |pmid=20101521 |pmc=2821513 |doi=10.1007/s10875-009-9357-x |url=}}</ref><ref name="pmid19153537">{{cite journal |vauthors=Suzuki H, Kaneko H, Fukao T, Jin R, Kawamoto N, Asano T, Matsui E, Kasahara K, Kondo N |title=Various expression patterns of alpha1 and alpha2 genes in IgA deficiency |journal=Allergol Int |volume=58 |issue=1 |pages=111–7 |date=March 2009 |pmid=19153537 |doi=10.2332/allergolint.O-08-549 |url=}}</ref><ref name="pmid11720003">{{cite journal |vauthors=Cunningham-Rundles C |title=Physiology of IgA and IgA deficiency |journal=J. Clin. Immunol. |volume=21 |issue=5 |pages=303–9 |date=September 2001 |pmid=11720003 |doi= |url=}}</ref><ref name="pmid15093556">{{cite journal |vauthors=Edwards E, Razvi S, Cunningham-Rundles C |title=IgA deficiency: clinical correlates and responses to pneumococcal vaccine |journal=Clin. Immunol. |volume=111 |issue=1 |pages=93–7 |date=April 2004 |pmid=15093556 |doi=10.1016/j.clim.2003.12.005 |url=}}</ref><ref name="pmid305332">{{cite journal |vauthors=Chipps BE, Talamo RC, Winkelstein JA |title=IgA deficiency, recurrent pneumonias, and bronchiectasis |journal=Chest |volume=73 |issue=4 |pages=519–26 |date=April 1978 |pmid=305332 |doi= |url=}}</ref><ref name="pmid5056860">{{cite journal |vauthors=Zinneman HH, Kaplan AP |title=The association of giardiasis with reduced intestinal secretory immunoglobulin A |journal=Am J Dig Dis |volume=17 |issue=9 |pages=793–7 |date=September 1972 |pmid=5056860 |doi= |url=}}</ref><ref name="pmid18683032">{{cite journal |vauthors=Aghamohammadi A, Cheraghi T, Gharagozlou M, Movahedi M, Rezaei N, Yeganeh M, Parvaneh N, Abolhassani H, Pourpak Z, Moin M |title=IgA deficiency: correlation between clinical and immunological phenotypes |journal=J. Clin. Immunol. |volume=29 |issue=1 |pages=130–6 |date=January 2009 |pmid=18683032 |doi=10.1007/s10875-008-9229-9 |url=}}</ref><ref name="pmid19541543">{{cite journal |vauthors=Janzi M, Kull I, Sjöberg R, Wan J, Melén E, Bayat N, Ostblom E, Pan-Hammarström Q, Nilsson P, Hammarström L |title=Selective IgA deficiency in early life: association to infections and allergic diseases during childhood |journal=Clin. Immunol. |volume=133 |issue=1 |pages=78–85 |date=October 2009 |pmid=19541543 |doi=10.1016/j.clim.2009.05.014 |url=}}</ref><ref name="pmid18202833">{{cite journal |vauthors=Jacob CM, Pastorino AC, Fahl K, Carneiro-Sampaio M, Monteiro RC |title=Autoimmunity in IgA deficiency: revisiting the role of IgA as a silent housekeeper |journal=J. Clin. Immunol. |volume=28 Suppl 1 |issue= |pages=S56–61 |date=May 2008 |pmid=18202833 |doi=10.1007/s10875-007-9163-2 |url=}}</ref><ref name="pmid10600329">{{cite journal |vauthors=Conley ME, Notarangelo LD, Etzioni A |title=Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies) |journal=Clin. Immunol. |volume=93 |issue=3 |pages=190–7 |date=December 1999 |pmid=10600329 |doi=10.1006/clim.1999.4799 |url=}}</ref><ref name="pmid4012343">{{cite journal |vauthors=Mayer RJ, Schiffer CA, Peterson BA, Silver RT, Cornwell GG, McIntyre OR, Rai KR, Budman DR, Ellison RR, Maguire M |title=Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I study |journal=Semin. Oncol. |volume=12 |issue=2 Suppl 3 |pages=84–90 |date=June 1985 |pmid=4012343 |doi= |url=}}</ref><ref name="pmid23527602">{{cite journal |vauthors=Massaad MJ, Ramesh N, Geha RS |title=Wiskott-Aldrich syndrome: a comprehensive review |journal=Ann. N. Y. Acad. Sci. |volume=1285 |issue= |pages=26–43 |date=May 2013 |pmid=23527602 |doi=10.1111/nyas.12049 |url=}}</ref><ref name="pmid29086100">{{cite journal |vauthors=Candotti F |title=Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome |journal=J. Clin. Immunol. |volume=38 |issue=1 |pages=13–27 |date=January 2018 |pmid=29086100 |doi=10.1007/s10875-017-0453-z |url=}}</ref><ref name="pmid28851742">{{cite journal |vauthors=Sereni L, Castiello MC, Villa A |title=Platelets in Wiskott-Aldrich syndrome: Victims or executioners? |journal=J. Leukoc. Biol. |volume=103 |issue=3 |pages=577–590 |date=March 2018 |pmid=28851742 |doi=10.1189/jlb.5MR0617-257R |url=}}</ref><ref name="pmid21178275">{{cite journal |vauthors=Blundell MP, Worth A, Bouma G, Thrasher AJ |title=The Wiskott-Aldrich syndrome: The actin cytoskeleton and immune cell function |journal=Dis. Markers |volume=29 |issue=3-4 |pages=157–75 |date=2010 |pmid=21178275 |pmc=3835520 |doi=10.3233/DMA-2010-0735 |url=}}</ref><ref name="pmid19351959">{{cite journal |vauthors=Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia Roncarolo M |title=Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome |journal=Blood |volume=113 |issue=25 |pages=6288–95 |date=June 2009 |pmid=19351959 |doi=10.1182/blood-2008-12-115253 |url=}}</ref><ref name="pmid11091267">{{cite journal |vauthors=Fischer A |title=Severe combined immunodeficiencies (SCID) |journal=Clin. Exp. Immunol. |volume=122 |issue=2 |pages=143–9 |date=November 2000 |pmid=11091267 |pmc=1905779 |doi= |url=}}</ref><ref name="pmid8462096">{{cite journal |vauthors=Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, McBride OW, Leonard WJ |title=Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans |journal=Cell |volume=73 |issue=1 |pages=147–57 |date=April 1993 |pmid=8462096 |doi= |url=}}</ref><ref name="pmid8961626">{{cite journal |vauthors=Puck JM |title=IL2RGbase: a database of gamma c-chain defects causing human X-SCID |journal=Immunol. Today |volume=17 |issue=11 |pages=507–11 |date=November 1996 |pmid=8961626 |doi= |url=}}</ref><ref name="pmid104530">{{cite journal |vauthors=Rowiński J, Souchier C, Czyba JC |title=DNA content of cells in human buccal smears. A preliminary study |journal=Acta Histochem. |volume=62 |issue=2 |pages=276–81 |date=1978 |pmid=104530 |doi=10.1016/S0065-1281(78)80093-2 |url=}}</ref><ref name="pmid3436096">{{cite journal |vauthors=Morgan G, Levinsky RJ, Hugh-Jones K, Fairbanks LD, Morris GS, Simmonds HA |title=Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency |journal=Clin. Exp. Immunol. |volume=70 |issue=3 |pages=491–9 |date=December 1987 |pmid=3436096 |pmc=1542189 |doi= |url=}}</ref><ref name="pmid11091267">{{cite journal |vauthors=Fischer A |title=Severe combined immunodeficiencies (SCID) |journal=Clin. Exp. Immunol. |volume=122 |issue=2 |pages=143–9 |date=November 2000 |pmid=11091267 |pmc=1905779 |doi= |url=}}</ref><ref name="pmid7401839">{{cite journal |vauthors=Ballard RW, Cummings CW |title=Job's syndrome |journal=Laryngoscope |volume=90 |issue=8 Pt 1 |pages=1367–70 |date=August 1980 |pmid=7401839 |doi= |url=}}</ref><ref name="pmid18424333">{{cite journal |vauthors=Freeman AF, Holland SM |title=The hyper-IgE syndromes |journal=Immunol Allergy Clin North Am |volume=28 |issue=2 |pages=277–91, viii |date=May 2008 |pmid=18424333 |pmc=2683262 |doi=10.1016/j.iac.2008.01.005 |url=}}</ref><ref name="pmid17881745">{{cite journal |vauthors=Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, Freeman AF, Demidowich A, Davis J, Turner ML, Anderson VL, Darnell DN, Welch PA, Kuhns DB, Frucht DM, Malech HL, Gallin JI, Kobayashi SD, Whitney AR, Voyich JM, Musser JM, Woellner C, Schäffer AA, Puck JM, Grimbacher B |title=STAT3 mutations in the hyper-IgE syndrome |journal=N. Engl. J. Med. |volume=357 |issue=16 |pages=1608–19 |date=October 2007 |pmid=17881745 |doi=10.1056/NEJMoa073687 |url=}}</ref><ref name="pmid17098478">{{cite journal |vauthors=Ling JC, Freeman AF, Gharib AM, Arai AE, Lederman RJ, Rosing DR, Holland SM |title=Coronary artery aneurysms in patients with hyper IgE recurrent infection syndrome |journal=Clin. Immunol. |volume=122 |issue=3 |pages=255–8 |date=March 2007 |pmid=17098478 |doi=10.1016/j.clim.2006.10.005 |url=}}</ref><ref name="pmid3338649">{{cite journal |vauthors=Hutto JO, Bryan CS, Greene FL, White CJ, Gallin JI |title=Cryptococcosis of the colon resembling Crohn's disease in a patient with the hyperimmunoglobulinemia E-recurrent infection (Job's) syndrome |journal=Gastroenterology |volume=94 |issue=3 |pages=808–12 |date=March 1988 |pmid=3338649 |doi= |url=}}</ref><ref name="pmid10673653">{{cite journal |vauthors=O'Connell AC, Puck JM, Grimbacher B, Facchetti F, Majorana A, Gallin JI, Malech HL, Holland SM |title=Delayed eruption of permanent teeth in hyperimmunoglobulinemia E recurrent infection syndrome |journal=Oral Surg Oral Med Oral Pathol Oral Radiol Endod |volume=89 |issue=2 |pages=177–85 |date=February 2000 |pmid=10673653 |doi=10.1067/moe.2000.103129 |url=}}</ref><ref name="pmid23883805">{{cite journal |vauthors=Tam JS, Routes JM |title=Common variable immunodeficiency |journal=Am J Rhinol Allergy |volume=27 |issue=4 |pages=260–5 |date=2013 |pmid=23883805 |pmc=3901442 |doi=10.2500/ajra.2013.27.3899 |url=}}</ref><ref name="pmid22180439">{{cite journal |vauthors=Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C |title=Morbidity and mortality in common variable immune deficiency over 4 decades |journal=Blood |volume=119 |issue=7 |pages=1650–7 |date=February 2012 |pmid=22180439 |pmc=3286343 |doi=10.1182/blood-2011-09-377945 |url=}}</ref><ref name="pmid18419489">{{cite journal |vauthors=Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, Viallard JF, Gardembas M, Galicier L, Schleinitz N, Suarez F, Soulas-Sprauel P, Hachulla E, Jaccard A, Gardeur A, Théodorou I, Rabian C, Debré P |title=Infections in 252 patients with common variable immunodeficiency |journal=Clin. Infect. Dis. |volume=46 |issue=10 |pages=1547–54 |date=May 2008 |pmid=18419489 |doi=10.1086/587669 |url=}}</ref><ref name="pmid3963038">{{cite journal |vauthors=Roifman CM, Rao CP, Lederman HM, Lavi S, Quinn P, Gelfand EW |title=Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia |journal=Am. J. Med. |volume=80 |issue=4 |pages=590–4 |date=April 1986 |pmid=3963038 |doi= |url=}}</ref><ref name="pmid21970952">{{cite journal |vauthors=Yong PF, Thaventhiran JE, Grimbacher B |title="A rose is a rose is a rose," but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011? |journal=Adv. Immunol. |volume=111 |issue= |pages=47–107 |date=2011 |pmid=21970952 |doi=10.1016/B978-0-12-385991-4.00002-7 |url=}}</ref><ref name="pmid16007087">{{cite journal |vauthors=Salzer U, Chapel HM, Webster AD, Pan-Hammarström Q, Schmitt-Graeff A, Schlesier M, Peter HH, Rockstroh JK, Schneider P, Schäffer AA, Hammarström L, Grimbacher B |title=Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans |journal=Nat. Genet. |volume=37 |issue=8 |pages=820–8 |date=August 2005 |pmid=16007087 |doi=10.1038/ng1600 |url=}}</ref><ref name="pmid17510807">{{cite journal |vauthors=Quinti I, Soresina A, Spadaro G, Martino S, Donnanno S, Agostini C, Claudio P, Franco D, Maria Pesce A, Borghese F, Guerra A, Rondelli R, Plebani A |title=Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency |journal=J. Clin. Immunol. |volume=27 |issue=3 |pages=308–16 |date=May 2007 |pmid=17510807 |doi=10.1007/s10875-007-9075-1 |url=}}</ref><ref name="pmid26564081">{{cite journal |vauthors=Nissenkorn A, Ben-Zeev B |title=Ataxia telangiectasia |journal=Handb Clin Neurol |volume=132 |issue= |pages=199–214 |date=2015 |pmid=26564081 |doi=10.1016/B978-0-444-62702-5.00014-7 |url=}}</ref><ref name="pmid27884168">{{cite journal |vauthors=Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM |title=Ataxia telangiectasia: a review |journal=Orphanet J Rare Dis |volume=11 |issue=1 |pages=159 |date=November 2016 |pmid=27884168 |pmc=5123280 |doi=10.1186/s13023-016-0543-7 |url=}}</ref><ref name="pmid9874856">{{cite journal |vauthors=Crawford TO |title=Ataxia telangiectasia |journal=Semin Pediatr Neurol |volume=5 |issue=4 |pages=287–94 |date=December 1998 |pmid=9874856 |doi= |url=}}</ref><ref name="pmid2415689">{{cite journal |vauthors=Boder E |title=Ataxia-telangiectasia: an overview |journal=Kroc Found Ser |volume=19 |issue= |pages=1–63 |date=1985 |pmid=2415689 |doi= |url=}}</ref><ref name="pmid22614068">{{cite journal |vauthors=Hoche F, Seidel K, Theis M, Vlaho S, Schubert R, Zielen S, Kieslich M |title=Neurodegeneration in ataxia telangiectasia: what is new? What is evident? |journal=Neuropediatrics |volume=43 |issue=3 |pages=119–29 |date=June 2012 |pmid=22614068 |doi=10.1055/s-0032-1313915 |url=}}</ref><ref name="pmid13542097">{{cite journal |vauthors=BODER E, SEDGWICK RP |title=Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection |journal=Pediatrics |volume=21 |issue=4 |pages=526–54 |date=April 1958 |pmid=13542097 |doi= |url=}}</ref><ref name="pmid24683014">{{cite journal |vauthors=Sahama I, Sinclair K, Pannek K, Lavin M, Rose S |title=Radiological imaging in ataxia telangiectasia: a review |journal=Cerebellum |volume=13 |issue=4 |pages=521–30 |date=August 2014 |pmid=24683014 |doi=10.1007/s12311-014-0557-4 |url=}}</ref><ref name="pmid23886747">{{cite journal |vauthors=Lin DD, Barker PB, Lederman HM, Crawford TO |title=Cerebral abnormalities in adults with ataxia-telangiectasia |journal=AJNR Am J Neuroradiol |volume=35 |issue=1 |pages=119–23 |date=January 2014 |pmid=23886747 |pmc=4106125 |doi=10.3174/ajnr.A3646 |url=}}</ref><ref name="pmid15069401">{{cite journal |vauthors=Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, Carson KA, Lederman HM |title=Immunodeficiency and infections in ataxia-telangiectasia |journal=J. Pediatr. |volume=144 |issue=4 |pages=505–11 |date=April 2004 |pmid=15069401 |doi=10.1016/j.jpeds.2003.12.046 |url=}}</ref>
+{|
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Disorder
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mechanism
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Characteristic Features
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical Presentation
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory Findings
+|-
+! align="center" style="background:#DCDCDC;" + |[[Wiskott-Aldrich syndrome|Wiskott-Aldrich Syndrome]]
+| align="left" style="background:#F5F5F5;" + |
+* [[Mutation]] in [[WAS]] [[gene]]
+* [[T cells]] unable to reorganize [[actin]] [[microfilaments]] ([[microfilament]] defect)
+| align="left" style="background:#F5F5F5;" + |
+* [[X-linked recessive]] pattern of inheritance
+* Increased risk of [[autoimmune disease]] and [[malignancy]]
+| align="left" style="background:#F5F5F5;" + |
+* [[Thrombocytopenic purpura]]
+* [[Eczema]]
+* Recurrent [[infections]]
+| align="left" style="background:#F5F5F5;" + |
+* Decreased to normal [[Immunoglobulin G|IgG]] and [[Immunoglobulin M|IgM]]
+* Increased [[Immunoglobulin E|IgE]] and [[IgA]]
+* Fewer and smaller [[platelets]]
+|-
+! align="center" style="background:#DCDCDC;" + |[[X-linked agammaglobulinemia|X-Linked (Bruton) Agammaglobulinemia]]
+| align="left" style="background:#F5F5F5;" + |
+* Defect in [[tyrosine kinase]] [[gene]] ([[Bruton's tyrosine kinase|BTK]])
+* [[B cells]] fail to mature
+| align="left" style="background:#F5F5F5;" + |
+* [[X-linked recessive]] pattern of inheritance
+* Increased [[prevalence]] in [[males]]
+| align="left" style="background:#F5F5F5;" + |
+* Recurrent [[bacterial]] and [[enteroviral]] [[infections]] after 6 months of age
+* Pre-disposition to development of [[infections]] by [[encapsulated organisms]]
+* Pre-disposition to development of Giardia infections
+* Absent lymph nodes and tonsils
+| align="left" style="background:#F5F5F5;" + |
+* Normal [[CD19|CD19+ B cell]] count
+* Decreased pro-[[B cells]]
+* Increased pre-[[B cells]]
+* Decreased [[immunoglobulins]] of all classes
+|-
+! align="center" style="background:#DCDCDC;" + |[[IgA deficiency|Selective IgA Deficiency]]
+| align="left" style="background:#F5F5F5;" + |
+* [[Stem cell]] defect (Transferrable with [[Bone marrow transplant|marrow transplant]])
+* Lack of [[Interleukin 4|IL-4]], [[Interleukin 6|IL-6]], [[Interleukin 7|IL-7]], [[Interleukin 10|IL-10]], [[TGF beta|TGF-β]], and [[Interleukin 21|IL-21]]
+* [[Mutations]] in [[transmembrane]] activator and calcium-modulator and [[cyclophilin]] ligand interactor ([[TACI]], [[TNFRSF13B]])
+| align="left" style="background:#F5F5F5;" + |
+* Most common primary [[immune deficiency]]
+| align="left" style="background:#F5F5F5;" + |
+* Majority of the cases are [[asymptomatic]]
+* Respiratory and [[gastrointestinal]] infections ([[mucosal]] infections)
+* Associated with [[autoimmune diseases]]
+* [[Atopy]]
+* [[Anaphylaxis]] to [[IgA]] containing products
+| align="left" style="background:#F5F5F5;" + |
+* Serum [[IgA]] < 7 mg/dl
+* Normal [[IgG]] and [[IgM]] levels
+|-
+! align="center" style="background:#DCDCDC;" + |[[Common variable immunodeficiency|Common Variable Immunodeficiency]]
+| align="left" style="background:#F5F5F5;" + |
+* Defective [[B cell]] differentiation
+| align="left" style="background:#F5F5F5;" + |
+* May be acquired in 20-30 years of age
+| align="left" style="background:#F5F5F5;" + |
+* May present with other [[autoimmune diseases]]
+* Associated with [[bronchiectasis]]
+* Associated with [[lymphoma]]
+* Associated with sinopulmonary infections ([[Bacterial]], [[enteroviral]] and [[parasitic]] such as [[Giardia]])
+| align="left" style="background:#F5F5F5;" + |
+* Decreased [[plasma cells]]
+* Decreased [[immunoglobulins]]
+|-
+! align="center" style="background:#DCDCDC;" + |[[Job's syndrome|Autosomal dominant hype IgE syndrome (Job's Syndrome)]]
+| align="left" style="background:#F5F5F5;" + |
+* Defieciency of [[T helper 17 cell|Th17 cells]] due to [[STAT3]] [[mutation]]
+* Impaired [[neutrophils]] to sites of [[infection]]
+| align="left" style="background:#F5F5F5;" + |
+* Distinctive coarse facies
+* Cold (non-inflammatory) Staphylococcal abscesses
+* Retained primary teeth
+* Eczema
+| align="left" style="background:#F5F5F5;" + |
+| align="left" style="background:#F5F5F5;" + |
+* Increased levels of [[IgE]]
+* Decreased levels of [[interferon gamma]] (IFN-gamma)
+|-
+! align="center" style="background:#DCDCDC;" + |[[Severe combined immunodeficiency|Severe combined immunodeficiency (SCID)]]
+| align="left" style="background:#F5F5F5;" + |
+* Defective [[Interleukin-2 receptor|interleukin-2 receptor gamma chain]]
+* [[Adenosine deaminase]] deficiency
+* Reg 1 and Reg 2 [[nonsense mutations]]
+| align="left" style="background:#F5F5F5;" + |
+* [[Interleukin 20 receptor, alpha subunit|IL-2R]] disease is [[X-linked]]
+* [[Adenosine deaminase|ADA]] deficiency and reg mutations are typically [[autosomal recessive]]
+| align="left" style="background:#F5F5F5;" + |
+* [[Failure to thrive]]
+* [[Chronic diarrhea]]
+* [[Thrush]]
+* Recurrent [[bacterial]], [[viral]] and [[protozoal]] infections
+* Treatment is [[bone marrow]] [[transplant]]
+| align="left" style="background:#F5F5F5;" + |
+* Decreased [[T cell]] receptor excision circles (TRECs)
+* Abscence of [[thymic]] shadow on [[Chest X-ray|chest X-Ray]]
+* Absent [[germinal centers]] of [[lymph node biopsy]]
+* Absent [[T cells]] on [[flow cytometry]]
+|-
+! align="center" style="background:#DCDCDC;" + |[[Ataxia telangiectasia|Ataxia Telangiectasia]]
+| align="left" style="background:#F5F5F5;" + |
+* Defect in [[ATM|ATM gene]]
+* [[DNA]] double stranded breaks leading to [[cell cycle]] arrest
+| align="left" style="background:#F5F5F5;" + |
+* Hypersensitivity to [[X-Ray|X-Rays]]
+| align="left" style="background:#F5F5F5;" + |
+* Triad of:
+** [[Ataxia]]
+** Spider [[Angioma|angiomas]] (Nests of distended [[capillaries]])
+** [[IgA deficiency]]
+| align="left" style="background:#F5F5F5;" + |
+* Increased [[alpha fetoprotein]] ([[Alpha-fetoprotein|AFP]])
+* Decreased [[IgA]], [[IgG]] and [[IgE]]
+* [[Lymphopenia]]
+* [[Cerebellar]] atrophy
+|-
+! align="center" style="background:#DCDCDC;" + |[[Hyper IgM Syndrome Type 1|Hyper IgM Syndrome]]
+| align="left" style="background:#F5F5F5;" + |
+* Defective [[CD40L]] ([[CD40L|CD40 ligand]]) on [[T helper cell|Th cells]] leading to [[class switching]] defect
+| align="left" style="background:#F5F5F5;" + |
+* [[X-linked recessive]] pattern of inheritance
+| align="left" style="background:#F5F5F5;" + |
+* Severe pyogenic infections in early life
+* Opportunistic infection with:
+** [[Pneumocystis jiroveci]]
+** [[Cryptosporidium]]
+** [[Cytomegalovirus]] ([[Cytomegalovirus infection|CMV]])
+| align="left" style="background:#F5F5F5;" + |
+* Increased [[Immunoglobulin M|IgM]]
+* Decreased [[Immunoglobulin G|IgG]], [[IgA]] and [[Immunoglobulin E|IgE]]
+* No [[germinal centers]]
+|}
+:*Malignancy: can cause the reduction in the immunoglobulin production.
+*Viral infections: such as Epstein-Barr virus, HIV, cytomegalovirus are other causes of hypogammaglobulinemia..
+*Side effect of certain medications: Some drugs include systemic glucocorticoids, phenytoin, and carbamazepine, have been associated with IgG deficiency.
+*Other causes of primary humoral immunodeficiencies.
+*Smoking: may cause IgG2 subclass deficiency.
+*Protein-losing conditions: enteropathies, nephrotic syndrome, burns, and other traumas may cause abnormal loss of immunoglobulins.
+==Differentiating Wiskott-Aldrich Syndrome From Other Bleeding Diseases==
+* Wiskott-Aldrich syndrome must be differentiated from other bleeding disorders. Different causes of bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings. These features have discussed in the below table:
+{|
+! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Category
+! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
+! colspan="2" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
+! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History
+! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical manifestation
+! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory testing
+! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
+|-
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
+|-
+! rowspan="15" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders
+! rowspan="6" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Qualitative Disorders of [[Platelet]] Function
+! rowspan="4" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of [[Platelet]] Function
+! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Wiskott-Aldrich syndrome]]
+| align="left" style="background:#F5F5F5;" |
+* Positive family history
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
+| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
+| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
+| align="center" style="background:#F5F5F5;" | −
+| align="center" style="background:#F5F5F5;" | −
+| align="center" style="background:#F5F5F5;" | Nl or ↓
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="left" style="background:#F5F5F5;" |
+* Anti-WASP antibody can be used to detect presence or absence of WAS protein
+* In Wiskott–Aldrich syndrome, the [[Platelet|platelets]] are small and do not function properly. They are removed by the [[spleen]], which leads to low [[platelet]] counts.
+|-
+! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Glanzmann's thrombasthenia|Glanzmann’s thrombasthenia]]
+| align="left" style="background:#F5F5F5;" |
+* Positive family history
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | −
+| align="center" style="background:#F5F5F5;" | Rare
+| align="center" style="background:#F5F5F5;" | Nl or ↓
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="left" style="background:#F5F5F5;" |
+* AR inheritance
+* Absence of the platelet Gp IIb/IIIa receptor
+* Diminished for GP 2B-3A on [[Flow cytometry|flow cytometry]]
+|-
+! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Bernard-Soulier syndrome]]
+| align="left" style="background:#F5F5F5;" |
+* Positive family history
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | −
+| align="center" style="background:#F5F5F5;" | −
+| align="center" style="background:#F5F5F5;" | Nl or ↓
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="left" style="background:#F5F5F5;" |
+* AR inheritance
+* Absence of the platelet Gp Ib-IX-V receptor
+* On PBS: giant platelets
+* Ristocetin - no aggregation
+|-
+! align="left" style="padding: 5px 5px; background: #DCDCDC;" |Platelet storage pool disorder:
+*[[Hermansky-Pudlak syndrome]]
+*[[Chediak-Higashi syndrome]]
+*[[Gray platelet syndrome]]
+| align="left" style="background:#F5F5F5;" |
+* Positive family history
+* [[Hairy cell leukemia]]
+* [[Cardiovascular bypass]]
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
+| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
+| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
+| align="center" style="background:#F5F5F5;" | −
+| align="center" style="background:#F5F5F5;" | −
+| align="center" style="background:#F5F5F5;" | Nl or ↓
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="left" style="background:#F5F5F5;" |
+* AD inheritance
+* AbNlities of platelet granule formation
+|-
+! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function
+| align="left" style="background:#F5F5F5 " |
+* [[Chronic renal failure pathophysiology|Uremia]]
+* [[Cardiopulmonary bypass]]
+* Hematologic disorders such as: [[Myeloproliferative disease|myeloproliferative]] and [[Myelodysplastic syndrome|myelodysplastic syndromes]]
+| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
+| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
+| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
+| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
+| align="center" style="background:#F5F5F5;" |±
+| align="center" style="background:#F5F5F5;" |±
+| align="center" style="background:#F5F5F5;" | Nl or ↓
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | −
+|-
+! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Von Willebrand disease|Von Willebrand Disease]]
+| align="left" style="background:#F5F5F5;" |
+* Easy bruising
+* [[Epistaxis]]
+* Oral cavity bleeding
+* Bleeding after dental extraction/surgery
+* [[Menorrhagia]]
+* [[Postpartum hemorrhage]]
+| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
+| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
+| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
+| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
+| align="center" style="background:#F5F5F5;" |±
+| align="center" style="background:#F5F5F5;" |±
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | See the table below for the details about different types.
+|-
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
+! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
+|-
+! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]]
+! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]]
+| align="left" style="background:#F5F5F5;" |
+* History of prior infection
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | ↓
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | −
+|-
+! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Medication]]-Induced [[Thrombocytopenia|Thrombocytopenia]]
+| align="left" style="background:#F5F5F5;" |
+*History of [[Medication|medications]] such as:
+** [[Furosemide]]
+** [[Non-steroidal anti-inflammatory drug|Nonsteroidal anti-inflammatory drugs]] ([[Non-steroidal anti-inflammatory drug|NSAIDs]])
+** [[Penicillin]]
+** [[Quinidine]]
+** [[Quinine]]
+** [[Ranitidine]]
+** [[Sulfonamide (medicine)|Sulfonamides]]
+** [[Linezolid]]
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | ↓
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication.
+|-
+! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Heparin-Induced Thrombocytopenia|Heparin-Induced thrombocytopenia]]
+| align="left" style="background:#F5F5F5;" |
+* [[Thrombosis]]
+* Unexplained [[thrombocytopenia]] up to 3 weeks after the end of [[heparin]] therapy
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | ↓
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]].
+|-
+! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]]
+| align="left" style="background:#F5F5F5;" |
+* History of prior [[infection]] or no history
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | ↓
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | −
+|-
+! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited [[Thrombocytopenia]]
+| align="left" style="background:#F5F5F5;" |
+* Positive family history
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | ↓
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | −
+|-
+! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]]
+| align="left" style="background:#F5F5F5;" | History of:
+*[[Cancer]]
+*[[Bone marrow transplantation]]
+*[[Pregnancy]]
+*[[Medication]]
+**[[Platelet]] aggregation inhibitors ([[ticlopidine]] and [[clopidogrel]])
+**Immunosuppressants ([[cyclosporine]], [[mitomycin]], [[tacrolimus]]/FK506, [[interferon|interferon-α]])
+*[[HIV-1]] infection
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | ↓
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | −
+|-
+! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]
+| align="left" style="background:#F5F5F5;" |History of:
+* [[Infections]]
+* [[Malignancy]], [[chemotherapy]], and [[ionizing radiation]]
+* [[Calcineurin inhibitor]]s and [[transplantation]]
+* [[Pregnancy]], [[HELLP syndrome]], and [[oral contraceptive pill]]
+* [[Systemic lupus erythematosis]]
+* [[Antiphospholipid syndrome|Antiphospholipid antibody syndrome]]
+* [[Glomerulopathy]]
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | ↓
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | −
+|-
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
+! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
+|-
+! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vessel wall disorders
+! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Metabolism|Metabolic]] and [[Inflammation|Inflammatory]] Disorders
+! colspan="2" align="left" style="padding: 5px 5px; background: #DCDCDC;" |
+* Acute febrile illnesses
+* [[Cryoglobulinemia|Mixed cryoglobulinemia]]
+* [[Monoclonal gammopathy|Monoclonal gammopathies]]
+* [[Rocky Mountain spotted fever]]
+* [[Vitamin C deficiency]]
+* [[Cushing's syndrome|Cushing’s syndrome]]
+* Chronic [[glucocorticoid]] therapy
+* [[Vasculitis]] such as Henoch-Schönlein Purpura
+| align="left" style="background:#F5F5F5;" |
+* History of the underlying disease
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" |±
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl or ↑
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |−
+|-
+! align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of the [[Vessel wall|Vessel Wall]]
+! colspan="2" align="left" style="background:#DCDCDC;" |
+* [[Marfan's syndrome|Marfan’s syndrome]]
+* [[Ehlers-Danlos syndrome]]
+* [[Pseudoxanthoma elasticum]]
+* [[Hereditary hemorrhagic telangiectasia]] ([[Hereditary hemorrhagic telangiectasia|HHT]], or [[Osler-Weber-Rendu|Osler-Weber-Rendu disease]])
+| align="left" style="background:#F5F5F5;" |
+* Positive family history
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" |±
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl or ↑
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |−
+|-
+! rowspan="15" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Coagulation factor disorders
+<ref name="pmid28966616" />
+! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Fibrinogen]] deficiency
+! colspan="2" align="left" style="padding: 5px 5px; background: #DCDCDC;" |
+Different types of the [[fibrinogen]] disorders:
+* [[Fibrinogen#Congenital afibrinogenemia|Congenital afibrinogenemia]]
+* [[Fibrinogen#Congenital hypofibrinogenemia|Congenital hypofibrinogenemia]]
+* [[Fibrinogen#Fibrinogen storage disease|Fibrinogen storage disease]]
+* [[Fibrinogen#Congenital dysfibrinogenemia|Congenital dysfibrinogenemia]]
+* [[Fibrinogen#Hereditary fibrinogen A.CE.B1-Chain amyloidosis|Hereditary fibrinogen Aα-Chain amyloidosis]]
+* [[Fibrinogen#Acquired dysfibrinogenemia|Acquired dysfibrinogenemia]]
+| align="left" style="background:#F5F5F5;" |
+* [[Epistaxis]]
+* Easy [[Bruise|bruising]]
+* [[Menorrhagia]]
+* [[Muscle]] bleeds
+* [[Hemarthrosis]]
+* [[Bleeding]] from the [[umbilical cord]] stump after birth
+* Bleeding after [[dental surgery]] or tooth extraction
+* AbNl bleeding during or after injury, surgery, or childbirth
+* [[Gastrointestinal tract|Gastrointestinal]] [[hemorrhage]]
+* [[Cerebral hemorrhage]]
+* [[Thrombosis]]
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" |±
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |↑
+| align="left" style="background:#F5F5F5;" |
+* Impaired fibrin cross-linking or clot dissolution
+* Mild or severe bleeding idepend on levels of functional fibrinogen
+* Variable age of onset
+|-
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
+! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
+|-
+! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Prothrombin deficiency]]
+| align="left" style="background:#F5F5F5;" |
+* [[Epistaxis]]
+* Soft-tissue hemorrhage
+* Excessive postoperative bleeding
+* [[Menorrhagia]]
+* Muscle [[Hematoma|hematomas]]
+* [[Hemarthrosis]]
+* [[Intracranial hemorrhage|Intracranial]] bleeding
+| align="center" style="background:#F5F5F5;" | −
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | Nl
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" | −
+|-
+! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor V deficiency]]
+| align="left" style="background:#F5F5F5;" |
+* Excessive bruising with minor injuries
+* [[Epistaxis]]
+* [[Hemarthrosis]]
+* [[Menorrhagia]]
+* [[Intracerebral hemorrhage|Intracerebral hemorrhages]]
+* [[Pulmonary hemorrhage]]
+| align="center" style="background:#F5F5F5;" | −
+| align="center" style="background:#F5F5F5;" | −
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |
+* The severity of bleeding related to the degree of factor V deficiency
+|-
+! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor VII deficiency]]
+| align="left" style="background:#F5F5F5;" |
+* Easy [[Bruise|bruising]]
+* Mucosal bleeding
+* Postoperative bleeding
+* [[Menorrhagia]]
+* Soft tissue hematomas
+* [[Thrombosis]]
+| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="left" style="background:#F5F5F5;" |
+* Thrombosis in inherited factor VII deficiency
+* Treatment with the administration of factor VII replacement therapy
+|-
+! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor X deficiency]]
+| align="left" style="background:#F5F5F5;" |
+* Prolonged bleeding following circumcision
+* Easy [[Bruise|bruising]]
+* [[Hematuria]]
+* [[Menorrhagia]]
+* Abortion
+* Postpartum hemorrhage
+* Epistaxis
+* Pseudotumors
+* Intracranial bleeding
+* Hemarthroses
+| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |−
+|-
+! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XII|Factor XII deficiency]]
+| align="left" style="background:#F5F5F5;" |
+* Asymptomatic
+* Recurrent miscarriages
+* Painful leg ulcers
+| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |
+|-
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
+! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
+|-
+! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[High-molecular-weight kininogen|High molecular weight kininogen (HMWK)]] deficiency
+| align="left" style="background:#F5F5F5;" |
+* Positive family history of bleeding
+| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |
+|-
+! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Prekallikrein]] deficiency
+| align="left" style="background:#F5F5F5;" |
+* Positive family history of bleeding
+| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |
+|-
+! rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XIII deficiency]]
+! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |
+* Sub unit A mutation disease (more common)
+* Sub unit B mutation disease
+| align="left" style="background:#F5F5F5;" |
+* Positive family history of bleeding
+| align="center" style="background:#F5F5F5;" |±
+| align="center" style="background:#F5F5F5;" |±
+| align="center" style="background:#F5F5F5;" |±
+| align="center" style="background:#F5F5F5;" |±
+| align="center" style="background:#F5F5F5;" |±
+| align="center" style="background:#F5F5F5;" |±
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl or ↑
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="left" style="background:#F5F5F5;" |
+* Impaired fibrin cross-linking or clot dissolution
+* The severity of factor XIII deficiency bleeds can be different in different patients
+|-
+! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]]
+! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency
+| align="left" style="background:#F5F5F5;" |
+* Eeasy [[Bruise|bruising]]
+* Inadequate clotting in [[trauma]] or mild injury
+* Spontaneous hemorrhage
+* [[Hemarthrosis]]
+* [[Epistaxis]]
+* [[Gingival bleeding]]
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |−
+|-
+! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type B deficiency
+| align="left" style="background:#F5F5F5;" |
+* Neonatal bleeding
+* Trauma-related soft tissue hemorrhage
+* [[Hemarthrosis]]
+* [[Hematoma|Hematomas]]
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |−
+|-
+! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type C deficiency
+| align="left" style="background:#F5F5F5;" |
+* Positive family history
+* Bleeding after surgery or injury
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" |Rare
+| align="center" style="background:#F5F5F5;" |Rare
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |−
+|-
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
+! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
+! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
+|-
+! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rare diseases
+! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]
+| align="left" style="background:#F5F5F5;" |
+* [[Trauma]]
+* [[Burn]]
+* [[Crush injury]]
+* [[Sepsis]]
+* [[Malignancy]]
+* Obstetric complication: abruption, amniotic fluid embolism
+* [[Hemolytic anemia]]
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" |↓
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |−
+|-
+! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Vitamin K Deficiency]]
+| align="left" style="background:#F5F5F5;" |
+* Bleeding after trauma
+* [[Epistaxis]]
+* [[Hematoma]]
+* Gastrointestinal bleeding
+* [[Menorrhagia]]
+* [[Hematuria]]
+* Gum bleeding
+* Oozing from venipuncture sites
+* Easy [[Bruise|bruisability]]
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" |−
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" | +
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |↑
+| align="center" style="background:#F5F5F5;" |Nl or mildly prolonged
+| align="center" style="background:#F5F5F5;" |Nl
+| align="center" style="background:#F5F5F5;" |−
+|}
+==Risk Factors==
+* Positive family history of Wiskott-Aldrich syndrome, can be considered as a risk factor.
+==Screening==
+*[[Flow cytometry]]:
+** Anti-WASp antibody can be used to detect presence or absence of WAS protein. However, [[flow cytometry]] may not detect expression of mutated, reduced or poor WASp.<ref name="pmid29729304">{{cite journal |vauthors=Chiang SCC, Vergamini SM, Husami A, Neumeier L, Quinn K, Ellerhorst T, Sheppard L, Gifford C, Buchbinder D, Joshi A, Ifversen M, Kleiner GI, Bussel JB, Chandrakasan S, Pesek RD, Pozos TC, Rose MJ, Scurlock AM, Zhang K, Bryceson YT, Bleesing J, Marsh RA |title=Screening for Wiskott-Aldrich syndrome by flow cytometry |journal=J. Allergy Clin. Immunol. |volume=142 |issue=1 |pages=333–335.e8 |date=July 2018 |pmid=29729304 |doi=10.1016/j.jaci.2018.04.017 |url=}}</ref>
+* Identification of carriers: Known [[female]] carriers can be identified by using [[DNA]] mutation analysis of WAS gene.
+* Prenatal diagnosis: [[DNA]] analysis from [[chorionic villus sampling]] can be performed.<ref name="pmid10073904">{{cite journal |vauthors=Giliani S, Fiorini M, Mella P, Candotti F, Schumacher RF, Wengler GS, Lalatta F, Fasth A, Badolato R, Ugazio AG, Albertini A, Notarangelo LD |title=Prenatal molecular diagnosis of Wiskott-Aldrich syndrome by direct mutation analysis |journal=Prenat. Diagn. |volume=19 |issue=1 |pages=36–40 |date=January 1999 |pmid=10073904 |doi= |url=}}</ref>
+==Natural History, Complications, and Prognosis==
+*If left untreated, [[Patient|patients]] with Wiscott-Aldrich syndrome may progress to develop manifestations associated with [[thrombocytopenia]], and abnormal platelet function, defective [[Innate immune system|innate]] and [[Adaptive immune system|adaptive immunity]] which include, severe [[bleeding]] (eg, [[epistaxis]], [[purpura]], life threatening [[Gastrointestinal tract|gastrointestinal]] and [[Intracranial hemorrhage|intracranial hemorrhages]]), recurrent and severe bronchopulmonary infections. Malignancy and [[autoimmunity]] risk has also increased. These conditions may increase the risk of death.<ref name="pmid7996359">{{cite journal |vauthors=Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA |title=A multiinstitutional survey of the Wiskott-Aldrich syndrome |journal=J. Pediatr. |volume=125 |issue=6 Pt 1 |pages=876–85 |date=December 1994 |pmid=7996359 |doi= |url=}}</ref>
+*Common complications of Wiscott-Aldrich syndrome include:
+** Recurrent infections with [[Bacteria|bacterial]], [[Virus|viral]], [[Fungus|fungal]] and [[Opportunistic infection|opportunistic organisms]]. Most common clinical manifestations include [[otitis media]], [[Rhinosinusitis|sinusitis]], [[pneumonia]], [[meningitis]], [[Skin and soft-tissue infections|skin infections]], and [[sepsis]].<ref name="pmid14159941">{{cite journal |vauthors=WEINTRAUB HD, WILSON WJ |title=PNEUMOCYSTIS CARINII PNEUMONIA IN WISKOTT-ALDRICH SYNDROME |journal=Am. J. Dis. Child. |volume=108 |issue= |pages=198–200 |date=August 1964 |pmid=14159941 |doi= |url=}}</ref><ref name="pmid24007832">{{cite journal |vauthors=Blancas-Galicia L, Escamilla-Quiroz C, Yamazaki-Nakashimada MA |title=[Wiskott-Aldrich Syndrome: An updated review] |language=Spanish; Castilian |journal=Rev Alerg Mex |volume=58 |issue=4 |pages=213–8 |date=2011 |pmid=24007832 |doi= |url=}}</ref><ref name="pmid12969986">{{cite journal |vauthors=Imai K, Morio T, Zhu Y, Jin Y, Itoh S, Kajiwara M, Yata J, Mizutani S, Ochs HD, Nonoyama S |title=Clinical course of patients with WASP gene mutations |journal=Blood |volume=103 |issue=2 |pages=456–64 |date=January 2004 |pmid=12969986 |doi=10.1182/blood-2003-05-1480 |url=}}</ref>
+** [[Bleeding diathesis]] (eg, [[epistaxis]], [[Bruise|ecchymoses]], [[Petechia|petechiae]], [[hematemesis]], [[Intracranial hemorrhage|intracranial]] and [[Gastrointestinal bleeding|gastrointestinal hemorrhages]])<ref name="pmid7996359">{{cite journal |vauthors=Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA |title=A multiinstitutional survey of the Wiskott-Aldrich syndrome |journal=J. Pediatr. |volume=125 |issue=6 Pt 1 |pages=876–85 |date=December 1994 |pmid=7996359 |doi= |url=}}</ref><ref name="pmid23449611">{{cite journal |vauthors=Notarangelo LD |title=In Wiskott-Aldrich syndrome, platelet count matters |journal=Blood |volume=121 |issue=9 |pages=1484–5 |date=February 2013 |pmid=23449611 |doi=10.1182/blood-2013-01-475913 |url=}}</ref>
+** Autoimmune manifestations may occur in the form of [[autoimmune hemolytic anemia]], [[immune thrombocytopenic purpura]] and [[neutropenia]], [[vasculitis]] involving small and large vessels, [[inflammatory bowel disease]], and  immune-mediated damage to the [[Kidney|kidneys]] and [[Joint|joints]].<ref name="pmid12728121">{{cite journal |vauthors=Dupuis-Girod S, Medioni J, Haddad E, Quartier P, Cavazzana-Calvo M, Le Deist F, de Saint Basile G, Delaunay J, Schwarz K, Casanova JL, Blanche S, Fischer A |title=Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients |journal=Pediatrics |volume=111 |issue=5 Pt 1 |pages=e622–7 |date=May 2003 |pmid=12728121 |doi= |url=}}</ref><ref name="pmid25877044">{{cite journal |vauthors=Chen N, Zhang ZY, Liu DW, Liu W, Tang XM, Zhao XD |title=The clinical features of autoimmunity in 53 patients with Wiskott-Aldrich syndrome in China: a single-center study |journal=Eur. J. Pediatr. |volume=174 |issue=10 |pages=1311–8 |date=October 2015 |pmid=25877044 |doi=10.1007/s00431-015-2527-3 |url=}}</ref><ref name="pmid29358862">{{cite journal |vauthors=Ohya T, Yanagimachi M, Iwasawa K, Umetsu S, Sogo T, Inui A, Fujisawa T, Ito S |title=Childhood-onset inflammatory bowel diseases associated with mutation of Wiskott-Aldrich syndrome protein gene |journal=World J. Gastroenterol. |volume=23 |issue=48 |pages=8544–8552 |date=December 2017 |pmid=29358862 |pmc=5752714 |doi=10.3748/wjg.v23.i48.8544 |url=}}</ref>
+** Increased risk of malignancy such as [[lymphoma]], [[Leukemia|leukaemia]] is a frequent occurence in Wiskott-Aldrich syndrome.<ref name="pmid3910193">{{cite journal |vauthors=Cotelingam JD, Witebsky FG, Hsu SM, Blaese RM, Jaffe ES |title=Malignant lymphoma in patients with the Wiskott-Aldrich syndrome |journal=Cancer Invest. |volume=3 |issue=6 |pages=515–22 |date=1985 |pmid=3910193 |doi= |url=}}</ref><ref name="pmid23023736">{{cite journal |vauthors=Yoshimi A, Kamachi Y, Imai K, Watanabe N, Nakadate H, Kanazawa T, Ozono S, Kobayashi R, Yoshida M, Kobayashi C, Hama A, Muramatsu H, Sasahara Y, Jakob M, Morio T, Ehl S, Manabe A, Niemeyer C, Kojima S |title=Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia |journal=Pediatr Blood Cancer |volume=60 |issue=5 |pages=836–41 |date=May 2013 |pmid=23023736 |doi=10.1002/pbc.24359 |url=}}</ref>
+*[[Prognosis]] is generally poor. 5-year [[Survival rate|survival rates]] in patients with Wiscott-Aldrich syndrome who had received [[stem cell transplantation]] is approximately  73.7% to 80%.<ref name="pmid17032176">{{cite journal |vauthors=Kobayashi R, Ariga T, Nonoyama S, Kanegane H, Tsuchiya S, Morio T, Yabe H, Nagatoshi Y, Kawa K, Tabuchi K, Tsuchida M, Miyawaki T, Kato S |title=Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan |journal=Br. J. Haematol. |volume=135 |issue=3 |pages=362–6 |date=November 2006 |pmid=17032176 |doi=10.1111/j.1365-2141.2006.06297.x |url=}}</ref>
 ==Diagnosis==
-[[Wiskott-Aldrich syndrome history and symptoms|History and Symptoms]] | [[Wiskott-Aldrich syndrome physical examination|Physical Examination]] | [[Wiskott-Aldrich syndrome laboratory findings|Laboratory Findings]] | [[Wiskott-Aldrich syndrome other diagnostic studies|Other Diagnostic Studies]]
+===Diagnostic Study of Choice===
+*The first laboratory test to be performed in the diagnosis of Wiskott-Aldrich syndrome is [[Complete blood count|complete blood count with differential]] and [[Blood film|peripheral blood smears]].
+*The diagnosis of Wiskott-Aldrich syndrome is suspected if a [[male]] patient who presents with [[Bruise|bruises]], [[Petechia|petechiae]], [[eczema]], recurrent [[Infection|infections]] and the presence of congenital [[thrombocytopenia]](< 70 000/mm3) with small [[platelet]] volume <5·0fl  (micro thrombocytopenia) on the [[Blood film|peripheral blood smear]].
+*Identification of  WAS gene mutations using [[DNA]] sequence analysis of WAS gene and detection of WASp expression by [[flow cytometry]] are necessary to confirm the diagnosis.<ref name="pmid15284122">{{cite journal |vauthors=Jin Y, Mazza C, Christie JR, Giliani S, Fiorini M, Mella P, Gandellini F, Stewart DM, Zhu Q, Nelson DL, Notarangelo LD, Ochs HD |title=Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation |journal=Blood |volume=104 |issue=13 |pages=4010–9 |date=December 2004 |pmid=15284122 |doi=10.1182/blood-2003-05-1592 |url=}}</ref><ref name="pmid12969986">{{cite journal |vauthors=Imai K, Morio T, Zhu Y, Jin Y, Itoh S, Kajiwara M, Yata J, Mizutani S, Ochs HD, Nonoyama S |title=Clinical course of patients with WASP gene mutations |journal=Blood |volume=103 |issue=2 |pages=456–64 |date=January 2004 |pmid=12969986 |doi=10.1182/blood-2003-05-1480 |url=}}</ref>
+===History and Symptoms===
+* Patients with Wiskott-Aldrich syndrome have
+* Common symptoms of Wiskott-Aldrich syndrome include:
+** [[Easy bruising]]
+** [[Petechia|Petechiae]]
+** [[Purpura]]
+** [[Eczema]]
+** Prolonged and excessive [[bleeding]] after circumcision or from umbilical stump
+** Recurrent [[Infection|infections]]
+** [[Epistaxis]] (Nose bleeds)
+** [[Hematemesis]]
+** [[Hematuria]]
+** [[Melena]]
+===Physical Examination===
+*The following findings may be found in the [[physical examination]] of the patients with Wiscott-Aldrich syndrome. These include:<ref name="pmid22523910">{{cite journal |vauthors=Suri D, Singh S, Rawat A, Gupta A, Kamae C, Honma K, Nakagawa N, Imai K, Nonoyama S, Oshima K, Mitsuiki N, Ohara O, Bilhou-Nabera C, Proust A, Ahluwalia J, Dogra S, Saikia B, Minz RW, Sehgal S |title=Clinical profile and genetic basis of Wiskott-Aldrich syndrome at Chandigarh, North India |journal=Asian Pac. J. Allergy Immunol. |volume=30 |issue=1 |pages=71–8 |date=March 2012 |pmid=22523910 |doi= |url=}}</ref><ref name="pmid2093894">{{cite journal |vauthors=De Bernardi A, Chessa Ricotti G, Galli L, Funis M |title=[Wiskott-Aldrich syndrome: description of a clinical case] |language=Italian |journal=Pediatr Med Chir |volume=12 |issue=6 |pages=691–3 |date=1990 |pmid=2093894 |doi= |url=}}</ref>
+**[[Failure to thrive]]
+**Skin examination shows [[Bruise|bruises]], [[Petechia|petechiae]], [[purpura]], and [[eczema]] due to low [[platelet]] count. suppurative [[skin]] lesions may also be seen.
+**[[Lymphadenopathy]]
+**[[Rales]] and [[Wheeze|wheezing]] on auscultation if there is an underlying [[Respiratory tract infection|lung infection]].
+**[[Hepatosplenomegaly]]
+**ENT examination: Carefully examine sinuses to rule out [[Rhinosinusitis|sinusitis]], [[Ear|ears]] for any [[Eardrum|tympanic membrane]] abnormalities to rule out [[otitis media]] and throat for [[pharyngitis]] and other opportunistic infections such as oral thrush.
+**CNS examination may be performed for symptoms associated with [[intracranial hemorrhage]] and [[Infection|infections]].
+===Laboratory Findings===
+*Laboratory findings consistent with the diagnosis of Wiscott-Aldrich syndrome include:
+** [[Complete blood count]] ([[Complete blood count|CBC]]) and [[Blood film|peripheral smear]] may show [[anemia]], [[thrombocytopenia]], decreased [[platelet]] size and volume.<ref name="pmid6444359">{{cite journal |vauthors=Ochs HD, Slichter SJ, Harker LA, Von Behrens WE, Clark RA, Wedgwood RJ |title=The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets |journal=Blood |volume=55 |issue=2 |pages=243–52 |date=February 1980 |pmid=6444359 |doi= |url=}}</ref>
+**Immunologic studies may show following findings:<ref name="pmid24817816">{{cite journal |vauthors=Buchbinder D, Nugent DJ, Fillipovich AH |title=Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments |journal=Appl Clin Genet |volume=7 |issue= |pages=55–66 |date=2014 |pmid=24817816 |pmc=4012343 |doi=10.2147/TACG.S58444 |url=}}</ref><ref name="pmid17218989">{{cite journal |vauthors=Humblet-Baron S, Sather B, Anover S, Becker-Herman S, Kasprowicz DJ, Khim S, Nguyen T, Hudkins-Loya K, Alpers CE, Ziegler SF, Ochs H, Torgerson T, Campbell DJ, Rawlings DJ |title=Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis |journal=J. Clin. Invest. |volume=117 |issue=2 |pages=407–18 |date=February 2007 |pmid=17218989 |pmc=1764857 |doi=10.1172/JCI29539 |url=}}</ref><ref name="pmid12177428">{{cite journal |vauthors=Orange JS, Ramesh N, Remold-O'Donnell E, Sasahara Y, Koopman L, Byrne M, Bonilla FA, Rosen FS, Geha RS, Strominger JL |title=Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue=17 |pages=11351–6 |date=August 2002 |pmid=12177428 |pmc=123260 |doi=10.1073/pnas.162376099 |url=}}</ref>
+*** Decreased levels of serum [[Immunoglobulin G|IgG]] and [[Immunoglobulin M|IgM]] and elevated levels of serum [[Immunoglobulin A|IgA]] and [[Immunoglobulin E|IgE]] antibodies.
+*** Reduction in [[T cell|T lymphocyte]] count and their function.
+*** Variable antibody response to  [[Vaccine|vaccines]], protein and polysaccharide [[Antigen|antigens]].
+*** Decreased or absent concentrations of [[Isohemagglutinin|isohemagglutinins]].
+*** Abnormal [[T cell|T]] and [[B cell|B lymphocyte]] proliferative response to [[Mitogen|mitogens]].
+*** Abnormal [[Phagocytosis|phagocytic response]]
+*** [[Natural killer cell|Natural Killer cell]] defects may also be found.
+===Electrocardiogram===
+* There are no specific [[electrocardiogram]] findings associated with Wiskott-Aldrich syndrome.
+===X-ray===
+*There are no specific [[X-rays|x-ray]] findings associated with Wiskott-Aldrich syndrome. However, a [[Chest X-ray|chest x-ray]] may be helpful in the diagnosis of complications, which include [[pneumonia]].
+===Echocardiography or Ultrasound===
+* There are no specific [[echocardiography]]/ [[ultrasound]] findings associated with Wiscott-Aldrich syndrome.
+===CT scan===
+*There are no [[Computed tomography|CT scan]] findings associated with Wiscott-Aldrich syndrome. However, a [[Computed tomography|CT scan]] may be helpful in the diagnosis of complications of this syndrome, which include [[pneumonia]], internal [[Bleeding|hemorrhage]], to diagnose [[Cancer|malignancy]] and to assess [[Splenomegaly|splenic enlargement]].<ref name="pmid27655432">{{cite journal |vauthors=Wu EY, Ehrlich L, Handly B, Frush DP, Buckley RH |title=Clinical and imaging considerations in primary immunodeficiency disorders: an update |journal=Pediatr Radiol |volume=46 |issue=12 |pages=1630–1644 |date=November 2016 |pmid=27655432 |pmc=5083248 |doi=10.1007/s00247-016-3684-x |url=}}</ref>
+===MRI===
+*There are no specific [[Magnetic resonance imaging|MRI]] findings associated with Wiskott-Aldrich syndrome.
 ==Treatment==
-[[Wiskott-Aldrich syndrome medical therapy|Medical Therapy]] | [[Wiskott-Aldrich syndrome surgery|Surgery]] | [[Wiskott-Aldrich syndrome prevention|Prevention]] | [[Wiskott-Aldrich syndrome cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Wiskott-Aldrich syndrome future or investigational therapies|Future or Investigational Therapies]]
+===Medical Therapy===
-==Case Studies==
+* Mainstay therapy for Wiskott-Aldrich syndrome is conservative therapy and supportive care, which includes:
-[[Wiskott-Aldrich syndrome case study one|Case #1]]
+** Prophylactic antimicrobial agents should be given to treat [[Bacteria|bacterial]], [[Virus|viral]], [[Fungus|fungal]] and [[Opportunistic infection|opportunistic infections]].<ref name="pmid8957959">{{cite journal |vauthors=Litzman J, Jones A, Hann I, Chapel H, Strobel S, Morgan G |title=Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome |journal=Arch. Dis. Child. |volume=75 |issue=5 |pages=436–9 |date=November 1996 |pmid=8957959 |pmc=1511781 |doi= |url=}}</ref><ref name="pmid27462353">{{cite journal |vauthors=Kim KR, Kim JM, Kang JM, Kim YJ |title=Pneumocystis jirovecii pneumonia in pediatric patients: an analysis of 15 confirmed consecutive cases during 14 years |journal=Korean J Pediatr |volume=59 |issue=6 |pages=252–5 |date=June 2016 |pmid=27462353 |pmc=4958702 |doi=10.3345/kjp.2016.59.6.252 |url=}}</ref>
+***[[Sulfamethoxazole-Trimethoprim|Trimethoprim/sulfamethoxazole]]: 5mg/kg/day can be given to treat most [[Bacteria|bacterial]] and [[pneumocystis jirovecii pneumonia]].
+***[[Acyclovir]]:  200mg/twice daily may be given to treat viral infections (eg, [[Herpes simplex|HSV-1]])<ref name="pmid8547009">{{cite journal |vauthors=Modiano P, Salloum E, Gillet-Terver MN, Barbaud A, Georges JC, Thouvenot D, Schmutz JL, Weber M |title=Acyclovir-resistant chronic cutaneous herpes simplex in Wiskott-Aldrich syndrome |journal=Br. J. Dermatol. |volume=133 |issue=3 |pages=475–8 |date=September 1995 |pmid=8547009 |doi= |url=}}</ref>
+***[[Fluconazole]]:  3mg/kg/day may be given to treat [[Fungal infection|fungal infections]].
+** [[Platelet]] transfusions:<ref name="pmid17654055">{{cite journal |vauthors=Ferrara M, Capozzi L, Coppola A, Save G, Coppola L |title=Prophylactic platelet transfusion in children with thrombocytopenic disorders: a retrospective review |journal=Hematology |volume=12 |issue=4 |pages=297–9 |date=August 2007 |pmid=17654055 |doi=10.1080/10245330701255213 |url=}}</ref>
+*** [[Platelet]] transfusions can be given to treat [[bleeding]] episodes such as life-threatening gastrointestinal and intracranial [[Bleeding|hemorrhages]]. [[Platelet]] transfusions can also be given to patients who are undergoing any surgical procedure.
+*** If a patient can be chosen for transfusion, [[Platelet|platelets]] and [[blood]] products should be irradiated and must be obtained from a [[Cytomegalovirus infection|CMV]] free donor.
+** [[Intravenous immunoglobulin|Intravenous immunoglobulins]]:<ref name="pmid5096517">{{cite journal |vauthors=Blaese RM, Strober W, Levy AL, Waldmann TA |title=Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome. A unique disorder of serum protein metabolism |journal=J. Clin. Invest. |volume=50 |issue=11 |pages=2331–8 |date=November 1971 |pmid=5096517 |pmc=292175 |doi=10.1172/JCI106731 |url=}}</ref>
+*** Preferred regimen:  400 to 600 mg/kg can be given every three weeks
+** [[Immunosuppressive agents]]:<ref name="pmid17498197">{{cite journal |vauthors=Kim JJ, Thrasher AJ, Jones AM, Davies EG, Cale CM |title=Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency |journal=Br. J. Haematol. |volume=138 |issue=1 |pages=94–6 |date=July 2007 |pmid=17498197 |doi=10.1111/j.1365-2141.2007.06616.x |url=}}</ref> [[Rituximab]] can be given to treat autoimmune cytopenias such as [[hemolytic anemia]], [[neutropenia]], associated with Wiskott- Aldrich syndrome.
+** [[Thrombopoietic agent|Thrombopoietic agents]]: [[Eltrombopag]] may be helpful in increasing [[platelet]] count in patients with Wiskott-Aldrich syndrome but it may not improve [[platelet]] surface activation.<ref name="pmid26224646">{{cite journal |vauthors=Gerrits AJ, Leven EA, Frelinger AL, Brigstocke SL, Berny-Lang MA, Mitchell WB, Revel-Vilk S, Tamary H, Carmichael SL, Barnard MR, Michelson AD, Bussel JB |title=Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia |journal=Blood |volume=126 |issue=11 |pages=1367–78 |date=September 2015 |pmid=26224646 |pmc=4729539 |doi=10.1182/blood-2014-09-602573 |url=}}</ref>
+** [[Gene therapy]]: [[Gene therapy]] is an alternative curative treatment for Wiskott-Aldrich syndrome, which is still going under trials.<ref name="pmid21067383">{{cite journal |vauthors=Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Díez IA, Dewey RA, Böhm M, Nowrouzi A, Ball CR, Glimm H, Naundorf S, Kühlcke K, Blasczyk R, Kondratenko I, Maródi L, Orange JS, von Kalle C, Klein C |title=Stem-cell gene therapy for the Wiskott-Aldrich syndrome |journal=N. Engl. J. Med. |volume=363 |issue=20 |pages=1918–27 |date=November 2010 |pmid=21067383 |pmc=3064520 |doi=10.1056/NEJMoa1003548 |url=}}</ref>
-==External links==
+===Surgery===
-*[http://www.primaryimmune.org/pubs/book_pats/book_pats.htm Immune Deficiency Foundation] - Chapter VII, "The Wiskott-Aldrich Syndrome"
+* [[Hematopoietic stem cell transplantation]] ([[Hematopoietic stem cell transplantation|HSCT]]):<ref name="pmid4177931">{{cite journal |vauthors=Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM |title=Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome |journal=Lancet |volume=2 |issue=7583 |pages=1364–6 |date=December 1968 |pmid=4177931 |doi= |url=}}</ref><ref name="pmid12598139">{{cite journal |vauthors=Antoine C, Müller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, Fasth A, Heilmann C, Wulffraat N, Seger R, Blanche S, Friedrich W, Abinun M, Davies G, Bredius R, Schulz A, Landais P, Fischer A |title=Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99 |journal=Lancet |volume=361 |issue=9357 |pages=553–60 |date=February 2003 |pmid=12598139 |doi= |url=}}</ref><ref name="pmid17710656">{{cite journal |vauthors=Muñoz A, Olivé T, Martinez A, Bureo E, Maldonado MS, Diaz de Heredia C, Sastre A, Gonzalez-Vicent M |title=Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) |journal=Pediatr Hematol Oncol |volume=24 |issue=6 |pages=393–402 |date=September 2007 |pmid=17710656 |doi=10.1080/08880010701454404 |url=}}</ref>
+** [[Hematopoietic stem cell transplantation|HSCT]] is the only standard curative treatment for Wiskott-Aldrich syndrome.
+* [[Splenectomy]]: Splenectomy may be considered for some patients with Wiskott-Aldrich syndrome . [[Splenectomy]] may be found to improve [[platelet]] count as well as size of the [[Platelet|platelets]] . However, [[sepsis]] is a life-threatening complication after [[splenectomy]]. Prophylactic [[Antibiotic|antibiotics]] should always be used to prevent [[Infection|infections]].<ref name="pmid6767187">{{cite journal |vauthors=Lum LG, Tubergen DG, Corash L, Blaese RM |title=Splenectomy in the management of the thrombocytopenia of the Wiskott-Aldrich syndrome |journal=N. Engl. J. Med. |volume=302 |issue=16 |pages=892–6 |date=April 1980 |pmid=6767187 |doi=10.1056/NEJM198004173021604 |url=}}</ref><ref name="pmid21906397">{{cite journal |vauthors=Syrigos KN, Makrilia N, Neidhart J, Moutsos M, Tsimpoukis S, Kiagia M, Saif MW |title=Prolonged survival after splenectomy in Wiskott-Aldrich syndrome: a case report |journal=Ital J Pediatr |volume=37 |issue= |pages=42 |date=September 2011 |pmid=21906397 |pmc=3179709 |doi=10.1186/1824-7288-37-42 |url=}}</ref>
-{{Immune disorders}}
+'''Primary Prevention'''
+*There are no established measures for the [[primary prevention]] of the Wiskott-Aldrich syndrome. However [[Genetic testing|genetic mutation analysis]] and [[Prenatal diagnosis|prenatal molecular diagnosis]] can be helpful in decreaing the occurance .<ref name="pmid8069912">{{cite journal |vauthors=Derry JM, Ochs HD, Francke U |title=Isolation of a novel gene mutated in Wiskott-Aldrich syndrome |journal=Cell |volume=78 |issue=4 |pages=635–44 |date=August 1994 |pmid=8069912 |doi= |url=}}</ref><ref name="pmid10073904">{{cite journal |vauthors=Giliani S, Fiorini M, Mella P, Candotti F, Schumacher RF, Wengler GS, Lalatta F, Fasth A, Badolato R, Ugazio AG, Albertini A, Notarangelo LD |title=Prenatal molecular diagnosis of Wiskott-Aldrich syndrome by direct mutation analysis |journal=Prenat. Diagn. |volume=19 |issue=1 |pages=36–40 |date=January 1999 |pmid=10073904 |doi= |url=}}</ref>
-[[Category:Genetic disorders]]
+===Secondary Prevention===
-[[Category:Immune system disorders]]
+* There are no established measures for the [[secondary prevention]] of the Wiskott-Aldrich syndrome.
+==References==
+{{reflist|2}}
+[[Category:Immunology]]
 [[Category:Hematology]]
-[[Category:Rare diseases]]
-[[de:Wiskott-Aldrich-Syndrom]]
-[[fr:Syndrome de Wiskott-Aldrich]]
-[[pl:Zespół Wiskotta-Aldricha]]
-[[pt:Síndrome de Wiskott-Aldrich]]
 {{WikiDoc Help Menu}}
 {{WikiDoc Sources}}